

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

This Page Blank (uspto)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/00		A2	(11) International Publication Number: WO 99/00410
			(43) International Publication Date: 7 January 1999 (07.01.99)
(21) International Application Number: PCT/US98/13012		(74) Agent: BILLINGS, Lucy, J.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).	
(22) International Filing Date: 23 June 1998 (23.06.98)			
(30) Priority Data: 08/884,072 27 June 1997 (27.06.97) US		(81) Designated States: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/884,072 (CIP) Filed on 27 June 1997 (27.06.97)			
(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).		Published Without international search report and to be republished upon receipt of that report.	
(72) Inventors; and (75) Inventors/Applicants (for US only): BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US).			

(54) Title: HUMAN EXTRACELLULAR MATRIX PROTEINS

9	18	27	36	45	54
CCA	AGA	TTG	TG	GAG	CAG
CTG	TGT	CCA	GAC	TGA	GGC
117	126	135	144	153	162
TGT	TCA	TTT	TTA	ACA	TTC
171	180	189	198	207	216
GGC	TAA	GCA	AAA	CCA	GGT
225	234	243	252	261	270
CCG	GCG	CTC	TCC	CCG	CCC
279	288	297	306	315	324
CAC	CCG	CGA	GCC	CCG	AGG
333	342	351	360	369	378
GGT	CCC	GCC	CGC	CGC	GTC
387	396	405	414	423	432
GAC	ATG	CCA	GGA	ATA	AAA
M	P	G	I	K	R
			L	T	V
			T	I	T
			L	A	L
			C	L	

(57) Abstract

The invention provides two human extracellular matrix proteins (ECMP) and polynucleotides which identify and encode ECMP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of ECMP.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CII	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

HUMAN EXTRACELLULAR MATRIX PROTEINS

TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of human extracellular matrix proteins and to the use of these sequences in the diagnosis, prevention, and treatment of cancer and immune disorders.

5

BACKGROUND OF THE INVENTION

Many eukaryotic cells are enveloped by an extracellular matrix of proteins that provide structural support, cell and tissue identity, and autocrine, paracrine and juxtacrine properties for the cell within its environment (McGowan, S.E. (1992) *FASEB J.* 6:2895-2904). The diverse 10 biochemistry of extracellular matrix proteins (ECMP) is indicative of the many, often overlapping, roles that are attributed to each distinct molecule (cf. Grant, D.S. and Kleinman, H.K. (1997) *E.X.S.* 79:317-333). Whilst a great number of ECMPs have been isolated, it still remains unclear how the majority interact with other ECMPs or with molecules residing within the cell membrane. Many ECMPs have been associated with tissue growth and cell proliferation, 15 others with tissue or cell differentiation, and yet others with cell death (cf. Taipale, J. and Keski-Oja, J. (1997) *FASEB J.* 11:51-59; Eleftheriou, C.S. et al. (1991) *Mutat. Res.* 256:127-138).

For example, the process of embryonic bone formation involves the creation of an extracellular matrix that mineralizes during the course of tissue maturation. During the life of an individual, this matrix is subject to constant remodeling, through the combined actions of 20 osteoblasts (which form mineralized bone) and osteoclasts (which resorb bone). The balance of ECMP composition, and the resulting bone structure, may be perturbed by biochemical changes that result from congenital, epigenetic, or infectious diseases (Francomano, C.A. et al. (1996) *Curr. Opin. Genet. Dev.* 6:301-308).

ECMPs also act as important mediators and regulators during the inflammatory response. 25 Leukocytes are primed for inflammatory mediator and cytokine production by binding to ECMPs during extravasation (Pakianathan, D.R. (1995) *J. Leukoc Biol.* 57:699-702). Deposition of ECMPs is also triggered by inflammation in response to lung injury (Roman, J. (1996) *Immunol. Res.* 15:163-178). Although the function of newly deposited matrices in injured lungs is unknown, their ability to affect the migration, proliferation, differentiation, and activation state of

cells in vitro suggested an important role in the initiation and maintenance of the inflammatory response in vivo (Roman, J. *supra*)

Some examples of recently identified ECMPs which regulate cellular and tissue differentiation are S1-5 and *Ecm1*. S1-5 mRNA is overexpressed both in senescent human fibroblasts established from a subject with Werner syndrome of premature ageing and in growth-arrested normal human fibroblasts (Lecka-Czernik, B. et al. (1995) *Mol. Cell. Biol.* 15:120-128). The mRNA encodes a 387 amino acid residue protein containing five epidermal growth factor (EGF)-like domains. These domains matched the EGF tandem repeat consensus within several known extracellular proteins that promote cell growth, development, and cell signaling. The EGF tandem repeat is characterized by a regular distribution of single cysteines. As occurs with other members of the EGF-like family, the S1-5 gene product may represent a negative and/or positive factor whose ultimate activity is modulated by the cell environment (Lecka-Czernik, B. *supra*).

Murine *Ecm1* encodes a 559 residue protein that has been localized to one genetic locus associated with developmental disorders of the skin (Bhalerao, J. et al. (1995) *J. Biol. Chem.* 270:16385-16394). During embryonic development, the gene is predominantly expressed in the form of splice variants in skin or cartilage tissue. Expression of the *Ecm1* gene also peaks during the late, pre-confluence phase of the murine osteogenic cell line, MN7, which proliferates and differentiates in vitro forming a mineralized matrix (Bhalerao, J. et al. (1995) *supra*). The murine *Ecm1* gene has been localized by genetic mapping to mouse chromosome 3, a region homologous to that of human chromosome 1q21 (Bhalerao, J. et al. (1995) *supra*). The molecular structure of the predicted protein is characterized by a pair of domains which share internal homology, and by a regular distribution of single cysteines and cysteine doublets. The latter arrangement was predicted to generate characteristic 'double-loop' proteins in the serum albumin family of proteins (Soltysik-Espanola, M. et al. (1994) *Dev. Biol.* 165:73-85). These double-loop' structures are involved in important ligand-binding functions (Kragh-Hansen, U. (1990) *Danish Med. Bull.* 37:57-84).

The discovery of new human extracellular matrix proteins and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention and treatment of cancer and immune disorders.

30

SUMMARY OF THE INVENTION

The invention features substantially purified human extracellular matrix proteins,

collectively referred to as ECMP and individually as ECMP-1, and ECMP-2, having the amino acid sequence shown in SEQ ID NO:1, or SEQ ID NO:3, respectively, or fragments thereof.

The invention further provides an isolated and substantially purified polynucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:1 or fragments thereof and a composition comprising said polynucleotide sequence. The invention 5 also provides a polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence encoding the amino acid sequence SEQ ID NO:1, or fragments of said polynucleotide sequence. The invention further provides a polynucleotide sequence comprising the complement of the polynucleotide sequence encoding the amino acid sequence of SEQ ID 10 NO:1, or fragments or variants of said polynucleotide sequence.

The invention also provides an isolated and purified sequence comprising SEQ ID NO.2 or variants thereof. In addition, the invention provides a polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence of SEQ ID NO:2. In another aspect the invention provides a composition comprising an isolated and purified 15 polynucleotide sequence comprising the complement of SEQ ID NO:2, or fragments or variants thereof. The invention also provides a polynucleotide sequence comprising the complement of SEQ ID NO:2.

The present invention further provides an expression vector containing at least a fragment of any of the claimed polynucleotide sequences. In yet another aspect, the expression vector 20 containing the polynucleotide sequence is contained within a host cell.

The invention also provides a method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment thereof, the method comprising the steps of: a) culturing the host cell containing an expression vector containing at least a fragment of the polynucleotide sequence encoding ECMP-1 under conditions suitable for the expression of the 25 polypeptide; and b) recovering the polypeptide from the host cell culture.

The invention also provides a pharmaceutical composition comprising a substantially purified ECMP-1 having the amino acid sequence of SEQ ID NO:1 in conjunction with a suitable pharmaceutical carrier.

The invention also provides a purified antagonist which decreases the activity of a 30 polypeptide of SEQ ID NO:1. In one aspect the invention provides a purified antibody which binds to a polypeptide comprising at least a fragment of the amino acid sequence of SEQ ID NO:1.

Still further, the invention provides a purified agonist which modulates the activity of the polypeptide of SEQ ID NO:1.

The invention also provides a method for treating or preventing cancer comprising administering to a subject in need of such treatment an effective amount of a purified antagonist of ECMP-1.

The invention also provides a method for treating or preventing an immune disorder comprising administering to a subject in need of such treatment an effective amount of a purified antagonist of ECMP-1.

The invention also provides a method for detecting a polynucleotide which encodes ECMP-1 in a biological sample comprising the steps of: a) hybridizing a polynucleotide sequence complementary to the polynucleotide sequence encoding ECMP-1 (SEQ ID NO:1) to nucleic acid material of a biological sample, thereby forming a hybridization complex; and b) detecting the hybridization complex, wherein the presence of the complex correlates with the presence of a polynucleotide encoding ECMP-1 in the biological sample. In a preferred embodiment, prior to hybridization, the nucleic acid material of the biological sample is amplified by the polymerase chain reaction.

The invention further provides an isolated and substantially purified polynucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:3 or fragments thereof and a composition comprising said polynucleotide sequence. The invention also provides a polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence encoding the amino acid sequence SEQ ID NO:3, or fragments of said polynucleotide sequence. The invention further provides a polynucleotide sequence comprising the complement of the polynucleotide sequence encoding the amino acid sequence of SEQ ID NO:3, or fragments or variants of said polynucleotide sequence.

The invention also provides an isolated and purified sequence comprising SEQ ID NO.4 or variants thereof. In addition, the invention provides a polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence of SEQ ID NO:4. In another aspect the invention provides a composition comprising an isolated and purified polynucleotide sequence comprising the complement of SEQ ID NO:4, or fragments or variants thereof. The invention also provides a polynucleotide sequence comprising the complement of SEQ ID NO:4.

The present invention further provides an expression vector containing at least a fragment

of any of the claimed polynucleotide sequences. In yet another aspect, the expression vector containing the polynucleotide sequence is contained within a host cell.

The invention also provides a method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:3 or a fragment thereof, the method comprising the steps of: a) 5 culturing the host cell containing an expression vector containing at least a fragment of the polynucleotide sequence encoding ECMP-2 under conditions suitable for the expression of the polypeptide; and b) recovering the polypeptide from the host cell culture.

The invention also provides a pharmaceutical composition comprising a substantially purified ECMP-2 having the amino acid sequence of SEQ ID NO:3 in conjunction with a suitable 10 pharmaceutical carrier.

The invention also provides a purified antagonist which decreases the activity of a polypeptide of SEQ ID NO:3. In one aspect the invention provides a purified antibody which binds to a polypeptide comprising at least a fragment of the amino acid sequence of SEQ ID NO:3.

15 Still further, the invention provides a purified agonist which modulates the activity of the polypeptide of SEQ ID NO:3.

The invention also provides a method for treating or preventing cancer comprising administering to a subject in need of such treatment an effective amount of a purified antagonist of ECMP-2.

20 The invention also provides a method for treating or preventing an immune disorder comprising administering to a subject in need of such treatment an effective amount of a purified antagonist of ECMP-2.

The invention also provides a method for detecting a polynucleotide which encodes 25 ECMP-2 in a biological sample comprising the steps of: a) hybridizing a polynucleotide sequence complementary to the polynucleotide sequence encoding ECMP-2 (SEQ ID NO:3) to nucleic acid material of a biological sample, thereby forming a hybridization complex; and b) detecting the hybridization complex, wherein the presence of the complex correlates with the presence of a polynucleotide encoding ECMP-2 in the biological sample. In a preferred embodiment, the nucleic acid material of the biological sample is amplified by the polymerase 30 chain reaction prior to hybridization.

BRIEF DESCRIPTION OF THE FIGURES

Figures 1A, 1B, 1C, 1D, 1E, 1F, and 1G show the amino acid sequence (SEQ ID NO:1) and nucleic acid sequence (SEQ ID NO:2) of ECMP-1. The alignment was produced using MacDNASIS PRO™ software (Hitachi Software Engineering Co. Ltd. San Bruno, CA).

5 Figures 2A, 2B, 2C, 2D, and 2E show the amino acid sequence (SEQ ID NO:3) and nucleic acid sequence (SEQ ID NO:4) of ECMP-2. The alignment was produced using MacDNASIS PRO™ software.

Figures 3A, and 3B show the amino acid sequence alignments between ECMP-1 (SEQ ID NO:1) and human S1-5 gene product (GI 458228; SEQ ID NO:5), produced using the 10 multisequence alignment program of DNASTAR™ software (DNASTAR Inc, Madison WI).

Figures 4A, 4B, and 4C show the amino acid sequence alignments between ECMP-2 (SEQ ID NO:3), and murine secreted protein encoded by *Ecm1* gene (GI 496120; SEQ ID NO:6), produced using the multisequence alignment program of DNASTAR™ software.

15 DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular methodology, protocols, cell lines, vectors, and reagents described, as these may vary. It is also to be understood that the 20 terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, reference to "a host cell" includes a plurality of such host cells, reference to the 25 "antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can 30 be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the cell lines, vectors, and methodologies

which are reported in the publications which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

5 DEFINITIONS

ECMP, as used herein, refers to the amino acid sequences of substantially purified ECMP obtained from any species, particularly mammalian, including bovine, ovine, porcine, murine, equine, and preferably human, from any source whether natural, synthetic, semi-synthetic, or recombinant.

10 The term "agonist", as used herein, refers to a molecule which, when bound to ECMP, increases or prolongs the duration of the effect of ECMP. Agonists may include proteins, nucleic acids, carbohydrates, or any other molecules which bind to and modulate the effect of ECMP.

15 An "allele" or "allelic sequence", as used herein, is an alternative form of the gene encoding ECMP. Alleles may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or polypeptides whose structure or function may or may not be altered. Any given natural or recombinant gene may have none, one, or many allelic forms. Common mutational changes which give rise to alleles are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

20 "Altered" nucleic acid sequences encoding ECMP as used herein include those with deletions, insertions, or substitutions of different nucleotides resulting in a polynucleotide that encodes the same or a functionally equivalent ECMP. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of the polynucleotide encoding ECMP, and improper or unexpected hybridization to 25 alleles, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding ECMP. The encoded protein may also be "altered" and contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent ECMP. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the 30 residues as long as the biological or immunological activity of ECMP is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid; positively charged amino acids may include lysine and arginine; and amino acids with uncharged polar head groups

having similar hydrophilicity values may include leucine, isoleucine, and valine, glycine and alanine, asparagine and glutamine, serine and threonine, and phenylalanine and tyrosine.

“Amino acid sequence” as used herein refers to an oligopeptide, peptide, polypeptide, or protein sequence, and fragment thereof, and to naturally occurring or synthetic molecules.

5 Fragments of ECMP are preferably about 5 to about 15 amino acids in length and retain the biological activity or the immunological activity of ECMP. Where “amino acid sequence” is recited herein to refer to an amino acid sequence of a naturally occurring protein molecule, amino acid sequence, and like terms, are not meant to limit the amino acid sequence to the complete, native amino acid sequence associated with the recited protein molecule.

10 “Amplification” as used herein refers to the production of additional copies of a nucleic acid sequence and is generally carried out using polymerase chain reaction (PCR) technologies well known in the art (Dieffenbach, C.W. and G.S. Dveksler (1995) PCR Primer, a Laboratory Manual, Cold Spring Harbor Press, Plainview, NY).

15 The term “antagonist” as used herein, refers to a molecule which, when bound to ECMP, decreases the amount or the duration of the effect of the biological or immunological activity of ECMP. Antagonists may include proteins, nucleic acids, carbohydrates, or any other molecules which decrease the effect of ECMP.

20 As used herein, the term “antibody” refers to intact molecules as well as fragments thereof, such as Fa, F(ab')₂, and Fv, which are capable of binding the epitopic determinant.

25 Antibodies that bind ECMP polypeptides can be prepared using intact polypeptides or fragments containing small peptides of interest as the immunizing antigen. The polypeptide or oligopeptide used to immunize an animal can be derived from the translation of RNA or synthesized chemically and can be conjugated to a carrier protein, if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin and thyroglobulin, keyhole limpet hemocyanin. The coupled peptide is then used to immunize the animal (e.g., a mouse, a rat, or a rabbit).

30 The term “antigenic determinant”, as used herein, refers to that fragment of a molecule (i.e., an epitope) that makes contact with a particular antibody. When a protein or fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to a given region or three-dimensional structure on the protein; these regions or structures are referred to as antigenic determinants. An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune

response) for binding to an antibody.

The term "antisense", as used herein, refers to any composition containing nucleotide sequences which are complementary to a specific DNA or RNA sequence. The term "antisense strand" is used in reference to a nucleic acid strand that is complementary to the "sense" strand.

5 Antisense molecules include peptide nucleic acids and may be produced by any method including synthesis or transcription. Once introduced into a cell, the complementary nucleotides combine with natural sequences produced by the cell to form duplexes and block either transcription or translation. The designation "negative" is sometimes used in reference to the antisense strand, and "positive" is sometimes used in reference to the sense strand.

10 The term "biologically active", as used herein, refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" refers to the capability of the natural, recombinant, or synthetic ECMP, or any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

15 The terms "complementary" or "complementarity", as used herein, refer to the natural binding of polynucleotides under permissive salt and temperature conditions by base-pairing. For example, the sequence "A-G-T" binds to the complementary sequence "T-C-A". Complementarity between two single-stranded molecules may be "partial", in which only some of the nucleic acids bind, or it may be complete when total complementarity exists between the 20 single stranded molecules. The degree of complementarity between nucleic acid strands has significant effects on the efficiency and strength of hybridization between nucleic acid strands. This is of particular importance in amplification reactions, which depend upon binding between nucleic acids strands and in the design and use of PNA molecules.

25 A "composition comprising a given polynucleotide sequence" as used herein refers broadly to any composition containing the given polynucleotide sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding ECMP (SEQ ID NO:1, SEQ ID NO:3) or fragments thereof (e.g., SEQ ID NO:2, or SEQ ID NO:4 and fragments thereof) may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as 30 a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., SDS) and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

“Consensus”, as used herein, refers to a nucleic acid sequence which has been resequenced to resolve uncalled bases, has been extended using XL-PCR™ (Perkin Elmer, Norwalk, CT) in the 5' and/or the 3' direction and resequenced, or has been assembled from the overlapping sequences of more than one Incyte Clone using a computer program for fragment assembly (e.g., GELVIEW™ Fragment Assembly system, GCG, Madison, WI). Some sequences have been both extended and assembled to produce the consensus sequence .

The term “correlates with expression of a polynucleotide”, as used herein, indicates that the detection of the presence of ribonucleic acid that is similar to SEQ ID NO:2, or SEQ ID NO:4 by northern analysis is indicative of the presence of mRNA encoding ECMP in a sample and thereby correlates with expression of the transcript from the polynucleotide encoding the protein.

A “deletion”, as used herein, refers to a change in the amino acid or nucleotide sequence and results in the absence of one or more amino acid residues or nucleotides.

The term “derivative”, as used herein, refers to the chemical modification of a nucleic acid encoding or complementary to ECMP or the encoded ECMP. Such modifications include, for example, replacement of hydrogen by an alkyl, acyl, or amino group. A nucleic acid derivative encodes a polypeptide which retains the biological or immunological function of the natural molecule. A derivative polypeptide is one which is modified by glycosylation, pegylation, or any similar process which retains the biological or immunological function of the polypeptide from which it was derived.

The term “homology”, as used herein, refers to a degree of complementarity. There may be partial homology or complete homology (i.e., identity). A partially complementary sequence that at least partially inhibits an identical sequence from hybridizing to a target nucleic acid is referred to using the functional term “substantially homologous.” The inhibition of hybridization of the completely complementary sequence to the target sequence may be examined using a hybridization assay (Southern or northern blot, solution hybridization and the like) under conditions of low stringency. A substantially homologous sequence or hybridization probe will compete for and inhibit the binding of a completely homologous sequence to the target sequence under conditions of low stringency. This is not to say that conditions of low stringency are such that non-specific binding is permitted; low stringency conditions require that the binding of two sequences to one another be a specific (i.e., selective) interaction. The absence of non-specific binding may be tested by the use of a second target sequence which lacks even a partial degree of complementarity (e.g., less than about 30% identity). In the absence of non-specific binding, the

probe will not hybridize to the second non-complementary target sequence.

Human artificial chromosomes (HACs) are linear microchromosomes which may contain DNA sequences of 10K to 10M in size and contain all of the elements required for stable mitotic chromosome segregation and maintenance (Harrington, J.J. et al. (1997) *Nat Genet.* 15:345-355).

5 The term "humanized antibody", as used herein, refers to antibody molecules in which amino acids have been replaced in the non-antigen binding regions in order to more closely resemble a human antibody, while still retaining the original binding ability.

The term "hybridization", as used herein, refers to any process by which a strand of nucleic acid binds with a complementary strand through base pairing.

10 The term "hybridization complex", as used herein, refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary G and C bases and between complementary A and T bases; these hydrogen bonds may be further stabilized by base stacking interactions. The two complementary nucleic acid sequences 15 hydrogen bond in an antiparallel configuration. A hybridization complex may be formed in solution (e.g., C_{0t} or R_{0t} analysis) or between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

20 An "insertion" or "addition", as used herein, refers to a change in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively, as compared to the naturally occurring molecule.

"Microarray" refers to an array of distinct polynucleotides or oligonucleotides synthesized on a substrate, such as paper, nylon or other type of membrane, filter, chip, glass slide, or any other suitable solid support.

25 The term "modulate", as used herein, refers to a change in the activity of ECMP. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional or immunological properties of ECMP.

30 "Nucleic acid sequence" as used herein refers to an oligonucleotide, nucleotide, or polynucleotide, and fragments thereof, and to DNA or RNA of genomic or synthetic origin which may be single- or double-stranded, and represent the sense or antisense strand. "Fragments" are those nucleic acid sequences which are greater than 60 nucleotides than in length, and most preferably includes fragments that are at least 100 nucleotides or at least 1000 nucleotides, and at

least 10,000 nucleotides in length.

The term "oligonucleotide" refers to a nucleic acid sequence of at least about 6 nucleotides to about 60 nucleotides, preferably about 15 to 30 nucleotides, and more preferably about 20 to 25 nucleotides, which can be used in PCR amplification or hybridization assays. As used herein, oligonucleotide is substantially equivalent to the terms "amplimers", "primers", "oligomers", and "probes", as commonly defined in the art.

"Peptide nucleic acid", PNA as used herein, refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least five nucleotides in length linked to a peptide backbone of amino acid residues which ends in lysine. The terminal lysine confers solubility to the composition. PNAs may be pegylated to extend their lifespan in the cell where they preferentially bind complementary single stranded DNA and RNA and stop transcript elongation (Nielsen, P.E. et al. (1993) *Anticancer Drug Des.* 8:53-63).

The term "portion", as used herein, with regard to a protein (as in "a portion of a given protein") refers to fragments of that protein. The fragments may range in size from five amino acid residues to the entire amino acid sequence minus one amino acid. Thus, a protein "comprising at least a portion of the amino acid sequence of SEQ ID NO:1, SEQ ID NO:3," encompasses the full-length ECMP and fragments thereof.

The term "sample", as used herein, is used in its broadest sense. A biological sample suspected of containing nucleic acid encoding ECMP, or fragments thereof, or ECMP itself may comprise a bodily fluid, extract from a cell, chromosome, organelle, or membrane isolated from a cell, a cell, genomic DNA, RNA, or cDNA (in solution or bound to a solid support, a tissue, a tissue print, and the like).

The terms "specific binding" or "specifically binding", as used herein, refers to that interaction between a protein or peptide and an agonist, an antibody and an antagonist. The interaction is dependent upon the presence of a particular structure (i.e., the antigenic determinant or epitope) of the protein recognized by the binding molecule. For example, if an antibody is specific for epitope "A", the presence of a protein containing epitope A (or free, unlabeled A) in a reaction containing labeled "A" and the antibody will reduce the amount of labeled A bound to the antibody.

The terms "stringent conditions" or "stringency", as used herein, refer to the conditions for hybridization as defined by the nucleic acid, salt, and temperature. These conditions are well known in the art and may be altered in order to identify or detect identical or related

polynucleotide sequences. Numerous equivalent conditions comprising either low or high stringency depend on factors such as the length and nature of the sequence (DNA, RNA, base composition), nature of the target (DNA, RNA, base composition), milieu (in solution or immobilized on a solid substrate), concentration of salts and other components (e.g., formamide, 5 dextran sulfate and/or polyethylene glycol), and temperature of the reactions (within a range from about 5°C below the melting temperature of the probe to about 20°C to 25°C below the melting temperature). One or more factors be may be varied to generate conditions of either low or high stringency different from, but equivalent to, the above listed conditions.

The term "substantially purified", as used herein, refers to nucleic or amino acid 10 sequences that are removed from their natural environment, isolated or separated, and are at least 60% free, preferably 75% free, and most preferably 90% free from other components with which they are naturally associated.

A "substitution", as used herein, refers to the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

"Transformation", as defined herein, describes a process by which exogenous DNA enters 15 and changes a recipient cell. It may occur under natural or artificial conditions using various methods well known in the art. Transformation may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method is selected based on the type of host cell being transformed and may include, but is not limited to, 20 viral infection, electroporation, heat shock, lipofection, and particle bombardment. Such "transformed" cells include stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome. They also include cells which transiently express the inserted DNA or RNA for limited periods of time.

A "variant" of ECMP, as used herein, refers to an amino acid sequence that is altered by 25 one or more amino acids. The variant may have "conservative" changes, wherein a substituted amino acid has similar structural or chemical properties, e.g., replacement of leucine with isoleucine. More rarely, a variant may have "nonconservative" changes, e.g., replacement of a glycine with a tryptophan. Analogous minor variations may also include amino acid deletions or 30 insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted without abolishing biological or immunological activity may be found using computer programs well known in the art, for example, DNASTAR software.

THE INVENTION

The invention is based on the discovery of a new human extracellular matrix proteins (collectively referred to as "ECMP" and individually, as ECMP-1 and ECMP-2), the polynucleotides encoding ECMP, and the use of these compositions for the diagnosis, prevention, 5 or treatment of cancer and immune disorders.

Nucleic acids encoding the ECMP-1 of the present invention were first identified in Incyte Clone 45517 from the corneal fibroblast cDNA library (CORNNOT01) using a computer search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:2, was derived from the following overlapping and/or extended nucleic acid sequences: Incyte Clones 45517 10 (CORNNOT01), 424333 (BLADNOT01), 1322651 (BLADNOT04), 198548 (KIDNNOT02), 944281 (ADRENOT03), and 953977 (SCORNON01).

In one embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:1, as shown in Figures 1A, 1B, 1C, 1D, 1E, 1F, and 1G. ECMP-1 is 449 amino acids in length and has five potential EGF-like tandem repeats between C-113 and C-15 341, four of which have the consensus repeat of Cx{11-12}Cx{5}Cx{4-6}Cx{3 or 5}Cx{8}Cx (where x represents any amino acid and {n} represents the number of residues). Within the EGF-like domain, there are four potential N-hydroxylation sites at N-146, N-183, N-223, and N-264; and two potential N-glycosylation sites, at N-283, and N-296. The N-terminal 19 amino acids 20 constitute a potential signal peptide sequence, and there is a potential cell attachment sequence, RGD, at R-54. There are eight potential casein kinase II phosphorylation sites at T-48, S-154, T-197, S-204, S-246, S-252, S-285, and S-385, and two potential protein kinase C phosphorylation sites at S-357, and at T-371. There is a potential prokaryotic membrane lipoprotein attachment 25 site between L-180 and C-190. As shown in Figures 3A and 3B, ECMP-1 has chemical and structural homology with human S1-5 gene product (GI 458228; SEQ ID NO:5). In particular, ECMP-1 shares 53% identity, an EGF-like tandem repeat motif, and potential N-hydroxylation sites with human S1-5 gene product. Northern analysis shows the expression of this sequence in 30 various libraries, at least 20% of which are immortalized or cancerous and at least 28% of which involve the immune response.

Nucleic acids encoding the ECMP-2 of the present invention were first identified in Incyte Clone 1621777 from the brain tumor tissue cDNA library (BRAITUT13) using a computer 35 search for amino acid sequence alignments. A consensus sequence, SEQ ID NO:4, was derived from the following overlapping and/or extended nucleic acid sequences: Incyte Clones 1621777

(BRAITUT13), 865787 (BRAITUT03), 1867044 (SKINBIT01), 1901493 (BLADTUT06) and 1957753 (CONNNOT01).

In another embodiment, the invention encompasses a polypeptide comprising the amino acid sequence of SEQ ID NO:3, as shown in Figures 2A, 2B, 2C, 2D, and 2E. ECMP-2 is 540 amino acids in length and has six potential cysteine repeats of single cysteines and cysteine doublets between C-181 and C-498. These repeats are characteristic of domains in the serum albumin family of proteins (Soltysik-Espanola, M. et al. (1994) *supra*). There is a potential N-terminal signal peptide between M-1 and A-20 and two internal homology domains between C-151 to Y-279 and C-284 to Y-405. In addition, ECMP-2 has three potential N-glycosylation sites at N-354, N-444, and N-530, five potential casein kinase II phosphorylation sites at residues S-138, S-293, T-391, S-490, and S-533, five potential protein kinase C phosphorylation sites at T-4, T-227, S-250, T-358, and T-446, and one potential tyrosine kinase phosphorylation site at Y-374.

As shown in Figures 4A, 4B, and 4C, ECMP-2 has chemical and structural homology with the secreted protein encoded by the murine *Ecm1* gene (GI 496120; SEQ ID NO:6). In particular, ECMP-2 shares 84% identity with mouse secreted protein. Both proteins share the single cysteine and cysteine doublet repeat domains. They share two of the potential N-glycosylation sites, three of the potential casein kinase II sites, and four of the potential protein kinase C sites. They also share the two internal sequence homology domains of *Ecm1*. Northern analysis shows the expression of this sequence in various libraries, at least 32% of which are immortalized or cancerous and at least 39% of which involve the immune response.

The invention also encompasses ECMP variants. A preferred ECMP variant is one having at least 80%, and more preferably 90%, amino acid sequence identity to the ECMP amino acid sequence (SEQ ID NO:1, or SEQ ID NO:3) and which retains at least one of the biological, structural or other functional characteristics of ECMP. A most preferred ECMP variant is one having at least 95% amino acid sequence identity to SEQ ID NO:1, or SEQ ID NO:3.

The invention also encompasses polynucleotides which encode ECMP. Accordingly, any nucleic acid sequence which encodes the amino acid sequence of ECMP can be used to produce recombinant molecules which express ECMP. In a particular embodiment, the invention encompasses the polynucleotide comprising the nucleic acid sequence of SEQ ID NO:2, or SEQ ID NO:4 as shown in Figures 1A, 1B, 1C, 1D, 1E, 1F, and 1G, Figures 2A, 2B, 2C, 2D, and 2E, respectively.

It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of nucleotide sequences encoding ECMP, some bearing minimal homology to the nucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring ECMP, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode ECMP and its variants are preferably capable of hybridizing to the nucleotide sequence of the naturally occurring ECMP under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding ECMP or its derivatives possessing a substantially different codon usage. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding ECMP and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences, or fragments thereof, which encode ECMP and its derivatives, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents that are well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding ECMP or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed nucleotide sequences, and in particular, those shown in SEQ ID NO:2, or SEQ ID NO:4, under various conditions of stringency as taught in Wahl, G.M. and S.L. Berger (1987; Methods Enzymol. 152:399-407) and Kimmel, A.R. (1987; Methods Enzymol. 152:507-511).

Methods for DNA sequencing which are well known and generally available in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, Sequenase® (US Biochemical Corp, Cleveland, OH), Taq polymerase (Perkin Elmer), thermostable T7 polymerase (Amersham,

Chicago, IL), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE Amplification System marketed by Gibco/BRL (Gaithersburg, MD). Preferably, the process is automated with machines such as the Hamilton Micro Lab 2200 (Hamilton, Reno, NV), Peltier Thermal Cycler (PTC200; MJ Research, Watertown, MA) and the 5 ABI Catalyst and 373 and 377 DNA Sequencers (Perkin Elmer).

The nucleic acid sequences encoding ECMP may be extended utilizing a partial nucleotide sequence and employing various methods known in the art to detect upstream sequences such as promoters and regulatory elements. For example, one method which may be employed, "restriction-site" PCR, uses universal primers to retrieve unknown sequence adjacent 10 to a known locus (Sarkar, G. (1993) PCR Methods Applic. 2:318-322). In particular, genomic DNA is first amplified in the presence of primer to a linker sequence and a primer specific to the known region. The amplified sequences are then subjected to a second round of PCR with the same linker primer and another specific primer internal to the first one. Products of each round 15 of PCR are transcribed with an appropriate RNA polymerase and sequenced using reverse transcriptase.

Inverse PCR may also be used to amplify or extend sequences using divergent primers based on a known region (Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186). The primers may be designed using commercially available software such as OLIGO 4.06 Primer Analysis 20 software (National Biosciences Inc., Plymouth, MN), or another appropriate program, to be 22-30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures about 68°-72° C. The method uses several restriction enzymes to generate a suitable fragment in the known region of a gene. The fragment is then circularized by intramolecular ligation and used as a PCR template.

Another method which may be used is capture PCR which involves PCR amplification of 25 DNA fragments adjacent to a known sequence in human and yeast artificial chromosome DNA (Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119). In this method, multiple restriction enzyme digestions and ligations may also be used to place an engineered double-stranded sequence into an unknown fragment of the DNA molecule before performing PCR.

30 Another method which may be used to retrieve unknown sequences is that of Parker, J.D. et al. (1991; Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PromoterFinder™ libraries to walk genomic DNA (Clontech, Palo Alto, CA). This process

avoids the need to screen libraries and is useful in finding intron/exon junctions. When screening for full-length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. Also, random-primed libraries are preferable, in that they will contain more sequences which contain the 5' regions of genes. Use of a randomly primed library may be especially preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different fluorescent dyes (one for each nucleotide) which are laser activated, and detection of the emitted wavelengths by a charge coupled device camera. Output/light intensity may be converted to electrical signal using appropriate software (e.g. Genotyper™ and Sequence Navigator™, Perkin Elmer) and the entire process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for the sequencing of small pieces of DNA which might be present in limited amounts in a particular sample.

In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode ECMP may be used in recombinant DNA molecules to direct expression of ECMP, fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced, and these sequences may be used to clone and express ECMP.

As will be understood by those of skill in the art, it may be advantageous to produce ECMP-encoding nucleotide sequences possessing non-naturally occurring codons. For example, codons preferred by a particular prokaryotic or eukaryotic host can be selected to increase the rate of protein expression or to produce an RNA transcript having desirable properties, such as a half-life which is longer than that of a transcript generated from the naturally occurring sequence.

The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter ECMP encoding sequences for a variety of reasons, including but not limited to, alterations which modify the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene

fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, site-directed mutagenesis may be used to insert new restriction sites, alter glycosylation patterns, change codon preference, produce splice variants, introduce mutations, and so forth.

In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding ECMP may be ligated to a heterologous sequence to encode a fusion protein. For example, to screen peptide libraries for inhibitors of ECMP activity, it may be useful to encode a chimeric ECMP protein that can be recognized by a commercially available antibody. A fusion protein may also be engineered to contain a cleavage site located between the ECMP encoding sequence and the heterologous protein sequence, so that ECMP may be cleaved and purified away from the heterologous moiety.

In another embodiment, sequences encoding ECMP may be synthesized, in whole or in part, using chemical methods well known in the art (see Caruthers, M.H. et al. (1980) *Nucl. Acids Res. Symp. Ser.* 215-223, Horn, T. et al. (1980) *Nucl. Acids Res. Symp. Ser.* 225-232). Alternatively, the protein itself may be produced using chemical methods to synthesize the amino acid sequence of ECMP, or a fragment thereof. For example, peptide synthesis can be performed using various solid-phase techniques (Roberge, J.Y. et al. (1995) *Science* 269:202-204) and automated synthesis may be achieved, for example, using the ABI 431A Peptide Synthesizer (Perkin Elmer).

The newly synthesized peptide may be substantially purified by preparative high performance liquid chromatography (e.g., Creighton, T. (1983) Proteins, Structures and Molecular Principles, WH Freeman and Co., New York, NY). The composition of the synthetic peptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; Creighton, *supra*). Additionally, the amino acid sequence of ECMP, or any part thereof, may be altered during direct synthesis and/or combined using chemical methods with sequences from other proteins, or any part thereof, to produce a variant polypeptide.

In order to express a biologically active ECMP, the nucleotide sequences encoding ECMP or functional equivalents, may be inserted into appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence.

Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding ECMP and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques,

synthetic techniques, and in vivo genetic recombination. Such techniques are described in Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview, NY, and Ausubel, F.M. et al. (1989) Current Protocols in Molecular Biology, John Wiley & Sons, New York, NY.

5 A variety of expression vector/host systems may be utilized to contain and express sequences encoding ECMP. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus); plant cell systems transformed with virus expression 10 vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems.

The invention is not limited by the host cell employed.

15 The "control elements" or "regulatory sequences" are those non-translated regions of the vector--enhancers, promoters, 5' and 3' untranslated regions--which interact with host cellular 20 proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, when cloning in bacterial systems, inducible promoters such as the hybrid lacZ promoter of the Bluescript® phagemid (Stratagene, LaJolla, CA) or pSport1™ plasmid 25 (Gibco/BRL) and the like may be used. The baculovirus polyhedrin promoter may be used in insect cells. Promoters or enhancers derived from the genomes of plant cells (e.g., heat shock, RUBISCO; and storage protein genes) or from plant viruses (e.g., viral promoters or leader sequences) may be cloned into the vector. In mammalian cell systems, promoters from mammalian genes or from mammalian viruses are preferable. If it is necessary to generate a cell 25 line that contains multiple copies of the sequence encoding ECMP, vectors based on SV40 or EBV may be used with an appropriate selectable marker.

30 In bacterial systems, a number of expression vectors may be selected depending upon the use intended for ECMP. For example, when large quantities of ECMP are needed for the induction of antibodies, vectors which direct high level expression of fusion proteins that are readily purified may be used. Such vectors include, but are not limited to, the multifunctional E. coli cloning and expression vectors such as Bluescript® (Stratagene), in which the sequence encoding ECMP may be ligated into the vector in frame with sequences for the amino-terminal

Met and the subsequent 7 residues of β -galactosidase so that a hybrid protein is produced: pIN vectors (Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509); and the like. pGEX vectors (Promega, Madison, WI) may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. Proteins made in such systems may be designed to include heparin, thrombin, or factor XA protease cleavage sites so that the cloned polypeptide of interest can be released from the GST moiety at will.

5 In the yeast, Saccharomyces cerevisiae, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase, and PGH may be used. For reviews, see Ausubel et al. (supra) and Grant et al. (1987) Methods Enzymol. 153:516-544.

10 In cases where plant expression vectors are used, the expression of sequences encoding ECMP may be driven by any of a number of promoters. For example, viral promoters such as the 35S and 19S promoters of CaMV may be used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) EMBO J. 6:307-311). Alternatively, plant 15 promoters such as the small subunit of RUBISCO or heat shock promoters may be used (Coruzzi, G. et al. (1984) EMBO J. 3:1671-1680; Broglie, R. et al. (1984) Science 224:838-843; and Winter, J. et al. (1991) Results Probl. Cell Differ. 17:85-105). These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. 20 Such techniques are described in a number of generally available reviews (see, for example, Hobbs, S. or Murry, L.E. in McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York, NY; pp. 191-196).

An insect system may also be used to express ECMP. For example, in one such system, Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign 25 genes in Spodoptera frugiperda cells or in Trichoplusia larvae. The sequences encoding ECMP may be cloned into a non-essential region of the virus, such as the polyhedrin gene, and placed under control of the polyhedrin promoter. Successful insertion of ECMP will render the polyhedrin gene inactive and produce recombinant virus lacking coat protein. The recombinant viruses may then be used to infect, for example, S. frugiperda cells or Trichoplusia larvae in 30 which ECMP may be expressed (Engelhard, E.K. et al. (1994) Proc. Nat. Acad. Sci. 91:3224-3227).

In mammalian host cells, a number of viral-based expression systems may be utilized. In

cases where an adenovirus is used as an expression vector, sequences encoding ECMP may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain a viable virus which is capable of expressing ECMP in infected host cells

5 (Logan, J. and Shenk, T. (1984) Proc. Natl. Acad. Sci. 81:3655-3659). In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained and expressed in a plasmid. HACs of 6 to 10M are constructed

10 and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes.

Specific initiation signals may also be used to achieve more efficient translation of sequences encoding ECMP. Such signals include the ATG initiation codon and adjacent sequences. In cases where sequences encoding ECMP, its initiation codon, and upstream

15 sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including the ATG initiation codon should be provided. Furthermore, the initiation codon should be in the correct reading frame to ensure translation of the entire insert. Exogenous translational elements and initiation

20 codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers which are appropriate for the particular cell system which is used, such as those described in the literature (Scharf, D. et al. (1994) Results Probl. Cell Differ. 20:125-162).

In addition, a host cell strain may be chosen for its ability to modulate the expression of

25 the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" form of the protein may also be used to facilitate correct insertion, folding and/or function. Different host cells which have specific cellular machinery and characteristic

30 mechanisms for post-translational activities (e.g., CHO, HeLa, MDCK, HEK293, and WI38), are available from the American Type Culture Collection (ATCC; Bethesda, MD) and may be chosen to ensure the correct modification and processing of the foreign protein.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express ECMP may be transformed using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the 5 introduction of the vector, cells may be allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be proliferated using tissue culture techniques appropriate to the cell type.

10 Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase (Wigler, M. et al. (1977) Cell 11:223-32) and adenine phosphoribosyltransferase (Lowy, I. et al. (1980) Cell 22:817-23) genes which can be employed in tk⁻ or aprt⁻ cells, respectively. Also, antimetabolite, 15 antibiotic or herbicide resistance can be used as the basis for selection; for example, dhfr which confers resistance to methotrexate (Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. 77:3567-70); npt, which confers resistance to the aminoglycosides neomycin and G-418 (Colbere-Garapin, F. et al (1981) J. Mol. Biol. 150:1-14) and als or pat, which confer resistance to chlorsulfuron and phosphinotricin acetyltransferase, respectively (Murry, supra). Additional selectable genes have 20 been described, for example, trpB, which allows cells to utilize indole in place of tryptophan, or hisD, which allows cells to utilize histinol in place of histidine (Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. 85:8047-51). Recently, the use of visible markers has gained popularity with such markers as anthocyanins, β glucuronidase and its substrate GUS, and luciferase and its substrate luciferin, being widely used not only to identify transformants, but 25 also to quantify the amount of transient or stable protein expression attributable to a specific vector system (Rhodes, C.A. et al. (1995) Methods Mol. Biol. 55:121-131). .

Although the presence/absence of marker gene expression suggests that the gene of interest is also present, its presence and expression may need to be confirmed. For example, if the sequence encoding ECMP is inserted within a marker gene sequence, transformed cells containing sequences encoding ECMP can be identified by the absence of marker gene function. 30 Alternatively, a marker gene can be placed in tandem with a sequence encoding ECMP under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates expression of the tandem gene as well.

Alternatively, host cells which contain the nucleic acid sequence encoding ECMP and express ECMP may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations and protein bioassay or immunoassay techniques which include membrane, solution, or chip based technologies for the detection and/or quantification of nucleic acid or protein.

The presence of polynucleotide sequences encoding ECMP can be detected by DNA-DNA or DNA-RNA hybridization or amplification using probes or fragments or fragments of polynucleotides encoding ECMP. Nucleic acid amplification based assays involve the use of oligonucleotides or oligomers based on the sequences encoding ECMP to detect transformants containing DNA or RNA encoding ECMP.

A variety of protocols for detecting and measuring the expression of ECMP, using either polyclonal or monoclonal antibodies specific for the protein are known in the art. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering epitopes on ECMP is preferred, but a competitive binding assay may be employed. These and other assays are described, among other places, in Hampton, R. et al. (1990; Serological Methods, a Laboratory Manual, APS Press, St Paul, MN) and Maddox, D.E. et al. (1983; J. Exp. Med. 158:1211-1216).

A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding ECMP include oligolabeling, nick translation, end-labeling or PCR amplification using a labeled nucleotide. Alternatively, the sequences encoding ECMP, or any fragments thereof may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits (Pharmacia & Upjohn, (Kalamazoo, MI); Promega (Madison WI); and U.S. Biochemical Corp., Cleveland, OH). Suitable reporter molecules or labels, which may be used for ease of detection, include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

Host cells transformed with nucleotide sequences encoding ECMP may be cultured under

conditions suitable for the expression and recovery of the protein from cell culture. The protein produced by a transformed cell may be secreted or contained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode ECMP may be designed to contain signal sequences which direct secretion of ECMP through a prokaryotic or eukaryotic cell membrane. Other constructions may be used to join sequences encoding ECMP to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins. Such purification facilitating domains include, but are not limited to, metal chelating peptides such as histidine-tryptophan modules that allow purification on immobilized metals, protein A domains that allow purification on immobilized immunoglobulin, and the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp., Seattle, WA). The inclusion of cleavable linker sequences such as those specific for Factor XA or enterokinase (Invitrogen, San Diego, CA) between the purification domain and ECMP may be used to facilitate purification. One such expression vector provides for expression of a fusion protein containing ECMP and a nucleic acid encoding 6 histidine residues preceding a thioredoxin or an enterokinase cleavage site. The histidine residues facilitate purification on IMAC (immobilized metal ion affinity chromatography as described in Porath, J. et al. (1992, *Prot. Exp. Purif.* 3: 263-281) while the enterokinase cleavage site provides a means for purifying ECMP from the fusion protein. A discussion of vectors which contain fusion proteins is provided in Kroll, D.J. et al. (1993; *DNA Cell Biol.* 12:441-453).

In addition to recombinant production, fragments of ECMP may be produced by direct peptide synthesis using solid-phase techniques Merrifield J. (1963) *J. Am. Chem. Soc.* 85:2149-2154). Protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be achieved, for example, using Applied Biosystems 431A Peptide Synthesizer (Perkin Elmer). Various fragments of ECMP may be chemically synthesized separately and combined using chemical methods to produce the full length molecule.

THERAPEUTICS

Chemical and structural homology exists among ECMP-1 and human S1-5 gene product (GI 458228). In addition, ECMP-1 is expressed in tissues associated with cancer and the immune response. Therefore, ECMP-1 appears to play a role in cancer and immune disorders, particularly disorders in which ECMP-1 is overexpressed.

Therefore, in one embodiment, an antagonist of ECMP-1 may be administered to a subject to prevent or treat cancer. Cancers may include, but are not limited to adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, and teratocarcinoma, and particularly cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, 5 ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus.

In another embodiment, a vector expressing the complement of the polynucleotide encoding ECMP-1 may be administered to a subject to treat or prevent cancer including, but not limited to, the types of cancer described above.

10 In another embodiment, an antagonist of ECMP-1 may be administered to a subject to prevent or treat an immune disorder. Such disorders may include, but are not limited to, AIDS, Addison's disease, adult respiratory distress syndrome, allergies, anemia, asthma, atherosclerosis, bronchitis, cholecystitis, Crohn's disease, ulcerative colitis, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythema nodosum, atrophic gastritis, 15 glomerulonephritis, gout, Graves' disease, hypereosinophilia, irritable bowel syndrome, lupus erythematosus, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, rheumatoid arthritis, scleroderma, Sjögren's syndrome, Werner syndrome, and autoimmune thyroiditis; complications of cancer, hemodialysis, extracorporeal circulation; viral, bacterial, fungal, parasitic, protozoal, and 20 helminthic infections and trauma.

In another embodiment, a vector expressing the complement of the polynucleotide encoding ECMP-1 may be administered to a subject to treat or prevent an immune disorder including, but not limited to, those described above.

25 In one aspect, antibodies which specifically bind ECMP-1 may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express ECMP-1.

Chemical and structural homology exists among ECMP-2 and murine secreted protein encoded by *Ecm1* gene (GI 496120). In addition, ECMP-2 is expressed in tissues associated with cancer and the immune response. Therefore, ECMP-2 appears to play a role in cancer and 30 immune disorders, particularly disorders in which ECMP-2 is overexpressed.

Therefore, in another embodiment, an antagonist of ECMP-2 may be administered to a subject to prevent or treat cancer. Cancers may include, but are not limited to, adenocarcinoma,

leukemia, lymphoma, melanoma, myeloma, sarcoma, and teratocarcinoma, and particularly cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus.

5 In another embodiment, a vector expressing the complement of the polynucleotide encoding ECMP-2 may be administered to a subject to treat or prevent a cancer including, but not limited to, any of the types of cancer described above.

In another embodiment, an antagonist of ECMP-2 may be administered to a subject to prevent or treat an immune disorder. Such disorders may include, but are not limited to, AIDS, 10 Addison's disease, adult respiratory distress syndrome, allergies, anemia, asthma, atherosclerosis, bronchitis, cholecystitus, Crohn's disease, ulcerative colitis, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythema nodosum, atrophic gastritis, glomerulonephritis, gout, Graves' disease, hypereosinophilia, irritable bowel syndrome, lupus erythematosus, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, 15 osteoarthritis, osteoporosis, pancreatitis, polymyositis, rheumatoid arthritis, scleroderma, Sjögren's syndrome, Werner syndrome, and autoimmune thyroiditis; complications of cancer, hemodialysis, extracorporeal circulation; viral, bacterial, fungal, parasitic, protozoal, and helminthic infections and trauma.

20 In another embodiment, a vector expressing the complement of the polynucleotide encoding ECMP-2 may be administered to a subject to treat or prevent an immune disorder including, but not limited to, those described above.

In one aspect, an antibody which specifically binds ECMP-2 may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissue which express ECMP-2.

25 In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary sequences or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment 30 or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

Antagonists or inhibitors of ECMP may be produced using methods which are generally known in the art. In particular, purified ECMP may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind ECMP.

Antibodies to ECMP may be generated using methods that are well known in the art.

5 Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies, (i.e., those which inhibit dimer formation) are especially preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others, may be immunized by injection with ECMP or any fragment or oligopeptide 10 thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and 15 Corynebacterium parvum are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to ECMP have an amino acid sequence consisting of at least five amino acids and more preferably at least 10 amino acids. It is also preferable that they are identical to a portion of the amino acid sequence of the natural protein, and they may contain the entire amino acid sequence of a small, 20 naturally occurring molecule. Short stretches of ECMP amino acids may be fused with those of another protein such as keyhole limpet hemocyanin and antibody produced against the chimeric molecule.

Monoclonal antibodies to ECMP may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are 25 not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique (Kohler, G. et al. (1975) *Nature* 256:495-497; Kozbor, D. et al. (1985) *J. Immunol. Methods* 81:31-42; Cote, R.J. et al. (1983) *Proc. Natl. Acad. Sci.* 80:2026-2030; Cole, S.P. et al. (1984) *Mol. Cell Biol.* 62:109-120).

In addition, techniques developed for the production of "chimeric antibodies", the splicing 30 of mouse antibody genes to human antibody genes to obtain a molecule with appropriate antigen specificity and biological activity can be used (Morrison, S.L. et al. (1984) *Proc. Natl. Acad. Sci.* 81:6851-6855; Neuberger, M.S. et al. (1984) *Nature* 312:604-608; Takeda, S. et al. (1985) *Nature*

314:452-454). Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce ECMP-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries (Burton D.R. 5 (1991) Proc. Natl. Acad. Sci. 88:11120-3).

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature (Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. 86: 3833-3837; Winter, G. et al. (1991) Nature 349:293-299).

10 Antibody fragments which contain specific binding sites for ECMP may also be generated. For example, such fragments include, but are not limited to, the F(ab')2 fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab')2 fragments. Alternatively, 15 Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse, W.D. et al. (1989) Science 254:1275-1281).

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between 20 ECMP and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering ECMP epitopes is preferred, but a competitive binding assay may also be employed (Maddox, *supra*).

In another embodiment of the invention, the polynucleotides encoding ECMP, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, the 25 complement of the polynucleotide encoding ECMP may be used in situations in which it would be desirable to block the transcription of the mRNA. In particular, cells may be transformed with sequences complementary to polynucleotides encoding ECMP. Thus, complementary molecules or fragments may be used to modulate ECMP activity, or to achieve regulation of gene function. Such technology is now well known in the art, and sense or antisense oligonucleotides or larger 30 fragments, can be designed from various locations along the coding or control regions of sequences encoding ECMP.

Expression vectors derived from retro viruses, adenovirus, herpes or vaccinia viruses, or

from various bacterial plasmids may be used for delivery of nucleotide sequences to the targeted organ, tissue or cell population. Methods which are well known to those skilled in the art can be used to construct vectors which will express nucleic acid sequence which is complementary to the polynucleotides of the gene encoding ECMP. These techniques are described both in 5 Sambrook et al. (supra) and in Ausubel et al. (supra).

Genes encoding ECMP can be turned off by transforming a cell or tissue with expression vectors which express high levels of a polynucleotide or fragment thereof which encodes ECMP. Such constructs may be used to introduce untranslatable sense or antisense sequences into a cell. Even in the absence of integration into the DNA, such vectors may continue to transcribe RNA 10 molecules until they are disabled by endogenous nucleases. Transient expression may last for a month or more with a non-replicating vector and even longer if appropriate replication elements are part of the vector system.

As mentioned above, modifications of gene expression can be obtained by designing 15 complementary sequences or antisense molecules (DNA, RNA, or PNA) to the control, 5' or regulatory regions of the gene encoding ECMP (signal sequence, promoters, enhancers, and introns). Oligonucleotides derived from the transcription initiation site, e.g., between positions -10 and +10 from the start site, are preferred. Similarly, inhibition can be achieved using "triple helix" base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the 20 ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature (Gee, J.E. et al. (1994) In: Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing Co., Mt. Kisco, NY). The complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

25 Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. Examples which may be used include engineered hammerhead motif ribozyme molecules that can specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding ECMP.

30 Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites which include the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20

ribonucleotides corresponding to the region of the target gene containing the cleavage site may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

5 Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by in vitro and in vivo transcription of DNA sequences encoding ECMP. Such DNA sequences may be
10 incorporated into a wide variety of vectors with suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA constitutively or inducibly can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3'
15 ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterate linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by
20 endogenous endonucleases.

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections or polycationic amino
25 polymers (Goldman, C.K. et al. (1997) Nature Biotechnology 15:462-66; incorporated herein by reference) may be achieved using methods which are well known in the art.

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

30 An additional embodiment of the invention relates to the administration of a pharmaceutical composition, in conjunction with a pharmaceutically acceptable carrier, for any of the therapeutic effects discussed above. Such pharmaceutical compositions may consist of

ECMP, antibodies to ECMP, mimetics, agonists, antagonists, or inhibitors of ECMP. The compositions may be administered alone or in combination with at least one other agent, such as stabilizing compound, which may be administered in any sterile, biocompatible pharmaceutical carrier, including, but not limited to, saline, buffered saline, dextrose, and water. The 5 compositions may be administered to a patient alone, or in combination with other agents, drugs or hormones.

The pharmaceutical compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, 10 intranasal, enteral, topical, sublingual, or rectal means.

In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found 15 in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, PA).

Pharmaceutical compositions for oral administration can be formulated using pharmaceutically acceptable carriers well known in the art in dosages suitable for oral administration. Such carriers enable the pharmaceutical compositions to be formulated as tablets, 20 pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

Pharmaceutical preparations for oral use can be obtained through combination of active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. 25 Suitable excipients are carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, or sodium carboxymethylcellulose; gums including arabic and tragacanth; and proteins such as gelatin and collagen. If desired, disintegrating or solubilizing agents may be added, such as the cross-linked polyvinyl 30 pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate.

Dragee cores may be used in conjunction with suitable coatings, such as concentrated sugar solutions, which may also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel,

polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for product identification or to characterize the quantity of active compound, i.e., dosage.

Pharmaceutical preparations which can be used orally include push-fit capsules made of 5 gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

10 Pharmaceutical formulations suitable for parenteral administration may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiologically buffered saline. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Additionally, suspensions of the active compounds may be 15 prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Non-lipid polycationic amino polymers may also be used for delivery. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

20 For topical or nasal administration, penetrants appropriate to the particular barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

The pharmaceutical compositions of the present invention may be manufactured in a manner that is known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping, or lyophilizing processes.

25 The pharmaceutical composition may be provided as a salt and can be formed with many acids, including but not limited to, hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms. In other cases, the preferred preparation may be a lyophilized powder which may contain any or all of the following: 1-50 mM histidine, 0.1%-2% sucrose, and 30 2-7% mannitol, at a pH range of 4.5 to 5.5, that is combined with buffer prior to use.

After pharmaceutical compositions have been prepared, they can be placed in an appropriate container and labeled for treatment of an indicated condition. For administration of

ECMP, such labeling would include amount, frequency, and method of administration.

Pharmaceutical compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models, usually mice, rabbits, dogs, or pigs. The animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

A therapeutically effective dose refers to that amount of active ingredient, for example ECMP or fragments thereof, antibodies of ECMP, agonists, antagonists or inhibitors of ECMP, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio between therapeutic and toxic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage varies within this range depending upon the dosage form employed, sensitivity of the patient, and the route of administration.

The exact dosage will be determined by the practitioner, in light of factors related to the subject that requires treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity of the disease state, general health of the subject, age, weight, and gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions may be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Guidance as to particular dosages and

methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

5

DIAGNOSTICS

In another embodiment, antibodies which specifically bind ECMP may be used for the diagnosis of conditions or disorders characterized by expression of ECMP, or in assays to monitor patients being treated with ECMP, agonists, antagonists or inhibitors. The antibodies useful for 10 diagnostic purposes may be prepared in the same manner as those described above for therapeutics. Diagnostic assays for ECMP include methods which utilize the antibody and a label to detect ECMP in human body fluids or extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by joining them, either covalently or non-covalently, with a reporter molecule. A wide variety of reporter molecules which are known in 15 the art may be used, several of which are described above.

A variety of protocols including ELISA, RIA, and FACS for measuring ECMP are known in the art and provide a basis for diagnosing altered or abnormal levels of ECMP expression. Normal or standard values for ECMP expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, preferably human, with antibody to ECMP 20 under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods, but preferably by photometric, means. Quantities of ECMP expressed in subject, control and disease, samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

25 In another embodiment of the invention, the polynucleotides encoding ECMP may be used for diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantitate gene expression in biopsied tissues in which expression of ECMP may be correlated with disease. The diagnostic assay may be used to distinguish between 30 absence, presence, and excess expression of ECMP, and to monitor regulation of ECMP levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting

polynucleotide sequences, including genomic sequences, encoding ECMP or closely related molecules, may be used to identify nucleic acid sequences which encode ECMP. The specificity of the probe, whether it is made from a highly specific region, e.g., 10 unique nucleotides in the 5' regulatory region, or a less specific region, e.g., especially in the 3' coding region, and the 5 stringency of the hybridization or amplification (maximal, high, intermediate, or low) will determine whether the probe identifies only naturally occurring sequences encoding ECMP, alleles, or related sequences.

Probes may also be used for the detection of related sequences, and should preferably contain at least 50% of the nucleotides from any of the ECMP encoding sequences. The 10 hybridization probes of the subject invention may be DNA or RNA and derived from the nucleotide sequence of SEQ ID NO:2, or SEQ ID NO:4 or from genomic sequence including promoter, enhancer elements, and introns of the naturally occurring ECMP.

Means for producing specific hybridization probes for DNAs encoding ECMP include the cloning of nucleic acid sequences encoding ECMP or ECMP derivatives into vectors for the 15 production of mRNA probes. Such vectors are known in the art, commercially available, and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, radionuclides such as 32P or 35S, or enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the 20 like.

Polynucleotide sequences encoding ECMP may be used for the diagnosis of conditions, or disorders which are associated with expression of ECMP. Examples of such conditions or diseases include cancer such as cancer of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, 25 ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; immune disorders such as AIDS, Addison's disease, adult respiratory distress syndrome, allergies, anemia, asthma, atherosclerosis, bronchitis, cholecystitus, Crohn's disease, ulcerative colitis, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, erythema nodosum, atrophic gastritis, glomerulonephritis, gout, Graves' disease, hypereosinophilia, 30 irritable bowel syndrome, lupus erythematosus, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, rheumatoid arthritis, scleroderma, Sjögren's syndrome, Werner syndrome, and autoimmune thyroiditis;

complications of cancer, hemodialysis, extracorporeal circulation; viral, bacterial, fungal, parasitic, protozoal, and helminthic infections and trauma. The polynucleotide sequences encoding ECMP may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; or in dipstick, pin, ELISA assays or 5 microarrays utilizing fluids or tissues from patient biopsies to detect altered ECMP expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding ECMP may be useful in assays that detect activation or induction of various cancers, particularly those mentioned above. The nucleotide sequences encoding ECMP may be labeled by standard methods, and added to a fluid 10 or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantitated and compared with a standard value. If the amount of signal in the biopsied or extracted sample is significantly altered from that of a comparable control sample, the nucleotide sequences have hybridized with nucleotide sequences in the sample, and the presence of altered levels of 15 nucleotide sequences encoding ECMP in the sample indicates the presence of the associated disease. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or in monitoring the treatment of an individual patient.

In order to provide a basis for the diagnosis of disease associated with expression of 20 ECMP, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, which encodes ECMP, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with those from an experiment where a known amount of a 25 substantially purified polynucleotide is used. Standard values obtained from normal samples may be compared with values obtained from samples from patients who are symptomatic for disease. Deviation between standard and subject values is used to establish the presence of disease.

Once disease is established and a treatment protocol is initiated, hybridization assays may be repeated on a regular basis to evaluate whether the level of expression in the patient begins to 30 approximate that which is observed in the normal patient. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ 5 preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Additional diagnostic uses for oligonucleotides designed from the sequences encoding ECMP may involve the use of PCR. Such oligomers may be chemically synthesized, generated enzymatically, or produced *in vitro*. Oligomers will preferably consist of two nucleotide 10 sequences, one with sense orientation (5'->3') and another with antisense (3'<-5'), employed under optimized conditions for identification of a specific gene or condition. The same two oligomers, nested sets of oligomers, or even a degenerate pool of oligomers may be employed under less stringent conditions for detection and/or quantitation of closely related DNA or RNA sequences.

15 Methods which may also be used to quantitate the expression of ECMP include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and standard curves onto which the experimental results are interpolated (Melby, P.C. et al. (1993) J. Immunol. Methods, 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 229-236). The speed of quantitation of multiple samples may be accelerated by running the assay in an ELISA format 20 where the oligomer of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides derived from any of the polynucleotide sequences described herein may be used as targets in microarrays. The microarrays can be used to monitor the expression level of large numbers of genes simultaneously (to produce a transcript 25 image), and to identify genetic variants, mutations and polymorphisms. This information will be useful in determining gene function, understanding the genetic basis of disease, diagnosing disease, and in developing and monitoring the activity of therapeutic agents (Heller, R. et al. (1997) Proc. Natl. Acad. Sci. 94:2150-55) .

30 In one embodiment, the microarray is prepared and used according to the methods described in PCT application WO95/11995 (Chee et al.), Lockhart, D. J. et al. (1996; Nat. Biotech. 14: 1675-1680) and Schena, M. et al. (1996; Proc. Natl. Acad. Sci. 93: 10614-10619), all of which are incorporated herein in their entirety by reference.

The microarray is preferably composed of a large number of unique, single-stranded nucleic acid sequences, usually either synthetic antisense oligonucleotides or fragments of cDNAs, fixed to a solid support. The oligonucleotides are preferably about 6-60 nucleotides in length, more preferably 15-30 nucleotides in length, and most preferably about 20-25 nucleotides
5 in length. For a certain type of microarray, it may be preferable to use oligonucleotides which are only 7-10 nucleotides in length. The microarray may contain oligonucleotides which cover the known 5', or 3', sequence, sequential oligonucleotides which cover the full length sequence; or unique oligonucleotides selected from particular areas along the length of the sequence.
10 Polynucleotides used in the microarray may be oligonucleotides that are specific to a gene or genes of interest in which at least a fragment of the sequence is known or that are specific to one or more unidentified cDNAs which are common to a particular cell type, developmental or disease state.

In order to produce oligonucleotides to a known sequence for a microarray, the gene of interest is examined using a computer algorithm which starts at the 5' or more preferably at the 3'
15 end of the nucleotide sequence. The algorithm identifies oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that may interfere with hybridization. In certain situations it may be appropriate to use pairs of oligonucleotides on a microarray. The "pairs" will be identical, except for one nucleotide which preferably is located in the center of the sequence. The second
20 oligonucleotide in the pair (mismatched by one) serves as a control. The number of oligonucleotide pairs may range from two to one million. The oligomers are synthesized at designated areas on a substrate using a light-directed chemical process. The substrate may be paper, nylon or other type of membrane, filter, chip, glass slide or any other suitable solid support.

25 In another aspect, the oligomers may be synthesized on the surface of the substrate by using a chemical coupling procedure and an ink jet application apparatus, as described in PCT application WO95/251116 (Baldeschweiler et al.) which is incorporated herein in its entirety by reference. In another aspect, a "gridded" array analogous to a dot (or slot) blot may be used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a
30 vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array may be produced by hand or using available devices (slot blot or dot blot apparatus), materials (any suitable solid support), and machines (including robotic instruments) and may contain 8, 24, 96,

384, 1536 or 6144 oligonucleotides, or any other multiple between two and one million which lends itself to the efficient use of commercially available instrumentation.

In order to conduct sample analysis using the microarrays, the RNA or DNA from a biological sample is made into hybridization probes. The mRNA is isolated, and cDNA is produced and used as a template to make antisense RNA (aRNA). The aRNA is amplified in the presence of fluorescent nucleotides, and labeled probes are incubated with the microarray so that the probe sequences hybridize to complementary oligonucleotides of the microarray. Incubation conditions are adjusted so that hybridization occurs with precise complementary matches or with various degrees of less complementarity. After removal of nonhybridized probes, a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine degree of complementarity and the relative abundance of each oligonucleotide sequence on the microarray. The biological samples may be obtained from any bodily fluids (such as blood, urine, saliva, phlegm, gastric juices, etc.), cultured cells, biopsies, or other tissue preparations. A detection system may be used to measure the absence, presence, and amount of hybridization for all of the distinct sequences simultaneously. This data may be used for large scale correlation studies on the sequences, mutations, variants, or polymorphisms among samples.

In another embodiment of the invention, the nucleic acid sequences which encode ECMP may also be used to generate hybridization probes which are useful for mapping the naturally occurring genomic sequence. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome or to artificial chromosome constructions, such as human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions or single chromosome cDNA libraries as reviewed in Price, C.M. (1993) *Blood Rev.* 7:127-134, and Trask, B.J. (1991) *Trends Genet.* 7:149-154.

Fluorescent in situ hybridization (FISH as described in Verma et al. (1988) Human Chromosomes: A Manual of Basic Techniques, Pergamon Press, New York, NY) may be correlated with other physical chromosome mapping techniques and genetic map data. Examples of genetic map data can be found in various scientific journals or at Online Mendelian Inheritance in Man (OMIM). Correlation between the location of the gene encoding ECMP on a physical chromosomal map and a specific disease, or predisposition to a specific disease, may help delimit the region of DNA associated with that genetic disease. The nucleotide sequences of the

subject invention may be used to detect differences in gene sequences between normal, carrier, or affected individuals.

5 In situ hybridization of chromosomal preparations and physical mapping techniques such as linkage analysis using established chromosomal markers may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the number or arm of a particular human chromosome is not known. New sequences can be assigned to chromosomal arms, or parts thereof, by physical mapping. This provides valuable information to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the disease or 10 syndrome has been crudely localized by genetic linkage to a particular genomic region, for example, AT to 11q22-23 (Gatti, R.A. et al. (1988) *Nature* 336:577-580), any sequences mapping to that area may represent associated or regulatory genes for further investigation. The nucleotide sequence of the subject invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc. among normal, carrier, or affected individuals.

15 In another embodiment of the invention, ECMP, its catalytic or immunogenic fragments or oligopeptides thereof, can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes, between ECMP and the agent being tested, may be measured.

20 Another technique for drug screening which may be used provides for high throughput screening of compounds having suitable binding affinity to the protein of interest as described in published PCT application WO84/03564. In this method, as applied to ECMP large numbers of different small test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The test compounds are reacted with ECMP, or fragments thereof, and washed. 25 Bound ECMP is then detected by methods well known in the art. Purified ECMP can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

30 In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding ECMP specifically compete with a test compound for binding ECMP. In this manner, the antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with ECMP.

In additional embodiments, the nucleotide sequences which encode ECMP may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such properties as the triplet genetic code and specific base pair interactions.

5 The examples below are provided to illustrate the subject invention and are not included for the purpose of limiting the invention.

EXAMPLES

I cDNA Library Construction

10 CORNNOT01

The corneal fibroblast CORNNOT01 cDNA library was custom constructed by Stratagene using stromal RNA isolated from the corneal fibroblasts of a 76-year-old. Stratagene prepared the cDNA library using an *Xba*I-oligo d(T) primer. Double-stranded cDNA was blunted, ligated to *Eco*RI adaptors, digested with *Xba*I, size-selected, and cloned into the *Xba*I and *Eco*RI sites of 15 the Lambda UniZAP™ vector (Stratagene). Following Lambda UniZAP™ packaging, 2×10^6 primary clones were then amplified to stabilize the library for long-term storage.

20 The quality of the cDNA library was screened using DNA probes, and then, the Bluescript® phagemid (Stratagene) was excised. Subsequently, the custom-constructed library phage particles were infected into *E. coli* host strain XL1-Blue® (Stratagene). Alternative unidirectional vectors include, but are not limited to, pcDNA1 (Invitrogen, Carlsbad, CA) and pSHlox-1 (Novagen, Madison WI).

BRAITUT13

25 The brain tumor BRAITUT13 cDNA library was constructed from cancerous brain tissue obtained from a 68-year-old Caucasian male during cerebral meningeal excision following diagnosis of meningioma localized in the left frontal part of the brain. In a prior surgery the patient had undergone a replacement of aortic valve with tissue graft.

30 The frozen tissue was homogenized and lysed using a Brinkmann Homogenizer Polytron PT-3000 (Brinkmann Instruments, Westbury, NJ) in guanidinium isothiocyanate solution. The lysate was centrifuged over a 5.7 M CsCl cushion using an Beckman SW28 rotor in a Beckman L8-70M Ultracentrifuge (Beckman Instruments) for 18 hours at 25,000 rpm at ambient temperature. The RNA was extracted with acid phenol pH 4.7, precipitated using 0.3 M sodium

acetate and 2.5 volumes of ethanol, resuspended in RNase-free water, and DNase treated at 37°C. Extraction and precipitation were repeated as before. The mRNA was then isolated with the Qiagen Oligotex kit (QIAGEN, Inc.; Chatsworth, CA) and used to construct the cDNA library.

5 The mRNA was handled according to the recommended protocols in the SuperScript Plasmid System for cDNA Synthesis and Plasmid Cloning (Cat. #18248-013; Gibco/BRL). cDNAs were fractionated on a Sepharose CL4B column (Cat. #275105-01; Pharmacia), and those cDNAs exceeding 400 bp were ligated into pSport I. The plasmid pSport I was subsequently transformed into DH5 α ™ competent cells (Cat. #18258-012; Gibco/BRL).

10

II Isolation and Sequencing of cDNA Clones

CORNNOT01

The phagemid forms of individual cDNA clones were obtained by the *in vivo* excision process, in which the host bacterial strain, XPORT *E. coli* (Stratagene, XL1 Blue strain) was 15 coinfected with both the lambda library phage (Lambda ZAP®II, Stratagene) and an f1 helper phage (Ex Assist, Stratagene). Polypeptides or enzymes derived from both the library-containing phage and the helper phage nicked the DNA, initiating new DNA synthesis from defined sequences on the target DNA and creating a smaller, single stranded circular phagemid DNA molecule that included all DNA, sequences of the pBluescript phagemid and the cDNA insert. 20 The phagemid DNA was released from the cells and purified, then used to re-infect fresh host cells (SOLR, Stratagene) where the double stranded DNA was produced. Because the phagemid carries the gene for β -lactamase, the newly-transformed bacteria were selected on medium containing ampicillin.

Phagemid DNA was purified using the QIAwell™-8 Plasmid Purification System, 25 QIAwell PLUS, or QIAwell ULTRA DNA purification system (QIAGEN, Inc., Chatsworth, CA). An alternative method for purifying the phagemid utilizes the Miniprep Kit available from Advanced Genetic Technologies Corp. (Gaithersburg, MD).

BRAITUT13

30 Plasmid DNA was released from the cells and purified using the REAL Prep 96 Plasmid Kit (Catalog #26173; QIAGEN, Inc.). The recommended protocol was employed except for the following changes: 1) the bacteria were cultured in 1 ml of sterile Terrific Broth (Catalog #22711,

Gibco/BRL) with carbenicillin at 25 mg/L and glycerol at 0.4%; 2) after inoculation, the cultures were incubated for 19 hours and at the end of incubation, the cells were lysed with 0.3 ml of lysis buffer; and 3) following isopropanol precipitation, the plasmid DNA pellet was resuspended in 0.1 ml of distilled water. After the last step in the protocol, samples were transferred to a 96-well

5 block for storage at 4° C.

The cDNAs were sequenced by the method of Sanger et al. (1975, *J. Mol. Biol.* 94:441f), using a Hamilton Micro Lab 2200 (Hamilton, Reno, NV) in combination with Peltier Thermal Cyclers (PTC200 from MJ Research, Watertown, MA) and Applied Biosystems 377 DNA Sequencing Systems.

10

III Homology Searching of cDNA Clones and Their Deduced Proteins

The nucleotide sequences of the Sequence Listing or amino acid sequences deduced from them were used as query sequences against databases such as GenBank, SwissProt, BLOCKS, and Pima II. These databases which contain previously identified and annotated sequences were 15 searched for regions of homology (similarity) using BLAST, which stands for Basic Local Alignment Search Tool (Altschul, S.F. (1993) *J. Mol. Evol.* 36:290-300; Altschul et al. (1990) *J. Mol. Biol.* 215:403-410).

BLAST produces alignments of both nucleotide and amino acid sequences to determine 20 sequence similarity. Because of the local nature of the alignments, BLAST is especially useful in determining exact matches or in identifying homologs which may be of prokaryotic (bacterial) or eukaryotic (animal, fungal or plant) origin. Other algorithms such as the one described in Smith R.F. and T.F. Smith (1992; *Protein Engineering* 5:35-51), incorporated herein by reference, can be used when dealing with primary sequence patterns and secondary structure gap penalties. As disclosed in this application, the sequences have lengths of at least 49 nucleotides, and no more 25 than 12% uncalled bases (where N is recorded rather than A, C, G, or T).

The BLAST approach, as detailed in Karlin, S. and S.F. Atschul (1993; *Proc. Nat. Acad. Sci.* 90:5873-7) and incorporated herein by reference, searches for matches between a query sequence and a database sequence, to evaluate the statistical significance of any matches found, and to report only those matches which satisfy the user-selected threshold of significance. In this 30 application, threshold was set at 10^{-25} for nucleotides and 10^{-14} for peptides.

Incyte nucleotide sequences were searched against the GenBank databases for primate (pri), rodent (rod), and mammalian sequences (mam), and deduced amino acid sequences from

the same clones are searched against GenBank functional protein databases, mammalian (mamp), vertebrate (vrtp) and eukaryote (eukp), for homology. The relevant database for a particular match were reported as a GIxxx±p (where xxx is pri, rod, etc and if present, p = peptide).

5 IV Northern Analysis

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound (Sambrook et al., *supra*).

Analogous computer techniques using BLAST (Altschul, S.F. 1993 and 1990, *supra*) are used to search for identical or related molecules in nucleotide databases such as GenBank or the LIFESEQ™ database (Incyte Pharmaceuticals). This analysis is much faster than multiple, membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or homologous.

The basis of the search is the product score which is defined as:

15 % sequence identity x % maximum BLAST score
100

The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. For example, with a product score of 40, the match will be exact within a 1-2% error; and at 70, the match will be exact. Homologous molecules are usually identified by selecting those which show product scores between 15 and 40, although lower scores may identify related molecules.

The results of northern analysis are reported as a list of libraries in which the transcript encoding ECMP occurs. Abundance and percent abundance are also reported. Abundance directly reflects the number of times a particular transcript is represented in a cDNA library, and percent abundance is abundance divided by the total number of sequences examined in the cDNA library.

V Extension of ECMP Encoding Polynucleotides

The nucleic acid sequence of the Incyte Clone 45517 or 162177 was used to design oligonucleotide primers for extending a partial nucleotide sequence to full length. One primer was synthesized to initiate extension in the antisense direction, and the other was synthesized to extend sequence in the sense direction. Primers were used to facilitate the extension of the

known sequence "outward" generating amplicons containing new, unknown nucleotide sequence for the region of interest. The initial primers were designed from the cDNA using OLIGO 4.06 (National Biosciences), or another appropriate program, to be about 22 to about 30 nucleotides in length, to have a GC content of 50% or more, and to anneal to the target sequence at temperatures 5 of about 68° to about 72° C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries (Gibco/BRL) were used to extend the sequence. If more than one extension is necessary or desired, additional sets of primers are designed to further extend the known region.

10 High fidelity amplification was obtained by following the instructions for the XL-PCR kit (Perkin Elmer) and thoroughly mixing the enzyme and reaction mix. Beginning with 40 pmol of each primer and the recommended concentrations of all other components of the kit, PCR was performed using the Peltier Thermal Cycler (PTC200; M.J. Research, Watertown, MA) and the following parameters:

15	Step 1	94° C for 1 min (initial denaturation)
	Step 2	65° C for 1 min
	Step 3	68° C for 6 min
	Step 4	94° C for 15 sec
	Step 5	65° C for 1 min
20	Step 6	68° C for 7 min
	Step 7	Repeat step 4-6 for 15 additional cycles
	Step 8	94° C for 15 sec
	Step 9	65° C for 1 min
	Step 10	68° C for 7:15 min
25	Step 11	Repeat step 8-10 for 12 cycles
	Step 12	72° C for 8 min
	Step 13	4° C (and holding)

30 A 5-10 μ l aliquot of the reaction mixture was analyzed by electrophoresis on a low concentration (about 0.6-0.8%) agarose mini-gel to determine which reactions were successful in extending the sequence. Bands thought to contain the largest products were excised from the gel, purified using QIAQuick™ (QIAGEN Inc., Chatsworth, CA), and trimmed of overhangs using Klenow enzyme to facilitate religation and cloning.

35 After ethanol precipitation, the products were redissolved in 13 μ l of ligation buffer, 1 μ l T4-DNA ligase (15 units) and 1 μ l T4 polynucleotide kinase were added, and the mixture was incubated at room temperature for 2-3 hours or overnight at 16° C. Competent E. coli cells (in 40 μ l of appropriate media) were transformed with 3 μ l of ligation mixture and cultured in 80 μ l

of SOC medium (Sambrook et al., *supra*). After incubation for one hour at 37° C, the *E. coli* mixture was plated on Luria Bertani (LB)-agar (Sambrook et al., *supra*) containing 2x Carb. The following day, several colonies were randomly picked from each plate and cultured in 150 μ l of liquid LB/2x Carb medium placed in an individual well of an appropriate, commercially-available, sterile 96-well microtiter plate. The following day, 5 μ l of each overnight culture was transferred into a non-sterile 96-well plate and after dilution 1:10 with water, 5 μ l of each sample was transferred into a PCR array.

For PCR amplification, 18 μ l of concentrated PCR reaction mix (3.3x) containing 4 units of rTth DNA polymerase, a vector primer, and one or both of the gene specific primers used for the extension reaction were added to each well. Amplification was performed using the following conditions:

Step 1	94° C for 60 sec
Step 2	94° C for 20 sec
Step 3	55° C for 30 sec
Step 4	72° C for 90 sec
Step 5	Repeat steps 2-4 for an additional 29 cycles
Step 6	72° C for 180 sec
Step 7	4° C (and holding)

Aliquots of the PCR reactions were run on agarose gels together with molecular weight markers. The sizes of the PCR products were compared to the original partial cDNAs, and appropriate clones were selected, ligated into plasmid, and sequenced.

In like manner, the nucleotide sequence of SEQ ID NO:2, or SEQ ID NO:4, is used to obtain 5' regulatory sequences using the procedure above, oligonucleotides designed for 5' extension, and an appropriate genomic library.

VI Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:2, or SEQ ID NO:4 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base-pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 (National Biosciences), labeled by combining 50 pmol of each oligomer and 250 μ Ci of [γ -³²P] adenosine triphosphate (Amersham) and T4 polynucleotide kinase (DuPont NEN[®], Boston, MA). The labeled oligonucleotides are substantially purified with Sephadex G-25 superfine resin column (Pharmacia & Upjohn). A aliquot containing 10⁷ counts per minute of

the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases (Ase I, Bgl II, Eco RI, Pst I, Xba 1, or Pvu II; DuPont NEN®).

The DNA from each digest is fractionated on a 0.7 percent agarose gel and transferred to 5 nylon membranes (Nytran Plus, Schleicher & Schuell, Durham, NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under increasingly stringent conditions up to 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. After XOMAT AR™ film (Kodak, Rochester, NY) is exposed to the blots in a Phosphoimager cassette (Molecular Dynamics, Sunnyvale, CA) for several hours, 10 hybridization patterns are compared visually.

VII Microarrays

To produce oligonucleotides for a microarray, the nucleotide sequence described herein is examined using a computer algorithm which starts at the 3' end of the nucleotide sequence. 15 The algorithm identifies oligomers of defined length that are unique to the gene, have a GC content within a range suitable for hybridization, and lack predicted secondary structure that would interfere with hybridization. The algorithm identifies 20 sequence-specific oligonucleotides of 20 nucleotides in length (20-mers). A matched set of oligonucleotides is created in which one nucleotide in the center of each sequence is altered. This process is repeated 20 for each gene in the microarray, and double sets of twenty 20 mers are synthesized and arranged on the surface of the silicon chip using a light-directed chemical process (Chee, M. et al., PCT/WO95/11995, incorporated herein by reference).

In the alternative, a chemical coupling procedure and an ink jet device are used to synthesize oligomers on the surface of a substrate (Baldeschweiler, J.D. et al., 25 PCT/WO95/25116, incorporated herein by reference). In another alternative, a "gridded" array analogous to a dot (or slot) blot is used to arrange and link cDNA fragments or oligonucleotides to the surface of a substrate using a vacuum system, thermal, UV, mechanical or chemical bonding procedures. An array may be produced by hand or using available materials and machines and contain grids of 8 dots, 24 dots, 96 dots, 384 dots, 1536 dots or 6144 dots. After 30 hybridization, the microarray is washed to remove nonhybridized probes, and a scanner is used to determine the levels and patterns of fluorescence. The scanned images are examined to determine degree of complementarity and the relative abundance of each oligonucleotide

sequence on the micro-array.

VIII Complementary Polynucleotides

Sequence complementary to the ECMP-encoding sequence, or any part thereof, is used 5 to decrease or inhibit expression of naturally occurring ECMP. Although use of oligonucleotides comprising from about 15 to about 30 base-pairs is described, essentially the same procedure is used with smaller or larger sequence fragments. Appropriate oligonucleotides are designed using Oligo 4.06 software and the coding sequence of ECMP, SEQ ID NO:1, or SEQ ID NO:3. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' 10 sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the ECMP-encoding transcript.

IX Expression of ECMP

15 Expression of ECMP is accomplished by subcloning the cDNAs into appropriate vectors and transforming the vectors into host cells. In this case, the cloning vector is also used to express ECMP in *E. coli*. Upstream of the cloning site, this vector contains a promoter for β -galactosidase, followed by sequence containing the amino-terminal Met, and the subsequent seven residues of β -galactosidase. Immediately following these eight residues is a bacteriophage 20 promoter useful for transcription and a linker containing a number of unique restriction sites.

Induction of an isolated, transformed bacterial strain with IPTG using standard methods produces a fusion protein which consists of the first eight residues of β -galactosidase, about 5 to 15 residues of linker, and the full length protein. The signal residues direct the secretion of ECMP into the bacterial growth media which can be used directly in the following assay for 25 activity.

X Demonstration of ECMP Activity

The activity of ECMP-1 and ECMP-2 may be measured using an assay based upon the 30 property of ECMPs to support proliferation *in vitro* of fibroblasts and tumor cells under serum-free conditions (Chiquet-Ehrismann, R, et al. (1986) Cell 47:131-139). Wells in 96 well cluster plates (Falcon, Fisher Scientific, Santa Clara, CA) are coated with ECMP by incubation with solutions at 50-100 μ g/ml for 15 min at ambient temperature. The coating solution is aspirated,

and the wells washed with Dulbecco's medium before cells are plated. Rat fibroblast cultures or rat mammary tumor cells are prepared as described and plated at a density of 10^4 - 10^5 cells/ml in Dulbecco's medium supplemented with 10% fetal calf serum.

After three days the media are removed, and the cells washed three times with phosphate-buffered saline (PBS) before the addition of serum-free Dulbecco's medium containing 0.25 mg/ml bovine serum albumin (BSA, Fraction V, Sigma Chemical, St. Louis, MO). After 2 days the medium is aspirated, and 100 μ l of [³H]thymidine (NEN) at 2 μ Ci/ml in fresh Dulbecco's medium containing 0.25 mg/ml BSA added. Parallel plates are fixed and stained to determine cell numbers. After 16 hr, the medium is aspirated, the cell layer washed with PBS, and the 10% trichloroacetic acid-precipitable counts in the cell layer determined by liquid scintillation counting of radioisotope (normalized to relative cell numbers; Chiquet-Ehrismann, R. et al. (1986) *supra*).

XI Production of ECMP Specific Antibodies

ECMP that is substantially purified using PAGE electrophoresis (Sambrook, *supra*), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols. The amino acid sequence deduced from SEQ ID NO:2, or SEQ ID NO:4 is analyzed using DNASTAR software (DNASTAR Inc) to determine regions of high immunogenicity and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions, is described by Ausubel et al. (*supra*), and others.

Typically, the oligopeptides are 15 residues in length, synthesized using an Applied Biosystems Peptide Synthesizer Model 431A using fmoc-chemistry, and coupled to keyhole limpet hemocyanin (KLH, Sigma, St. Louis, MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS; Ausubel et al., *supra*). Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. The resulting antisera are tested for antipeptide activity, for example, by binding the peptide to plastic, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio iodinated, goat anti-rabbit IgG.

30 XII Purification of Naturally Occurring ECMP Using Specific Antibodies

Naturally occurring or recombinant ECMP is substantially purified by immunoaffinity chromatography using antibodies specific for ECMP. An immunoaffinity column is constructed

by covalently coupling ECMP antibody to an activated chromatographic resin, such as CNBr-activated Sepharose (Pharmacia & Upjohn). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing ECMP is passed over the immunoaffinity column, and the column is
5 washed under conditions that allow the preferential absorbance of ECMP (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/ECMP binding (eg, a buffer of pH 2-3 or a high concentration of a chaotrope, such as urea or thiocyanate ion), and ECMP is collected.

10 **XIII Identification of Molecules Which Interact with ECMP**

ECMP or biologically active fragments thereof are labeled with ^{125}I Bolton-Hunter reagent (Bolton et al. (1973) Biochem. J. 133: 529). Candidate molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled ECMP, washed and any wells with labeled ECMP complex are assayed. Data obtained using different concentrations of ECMP are
15 used to calculate values for the number, affinity, and association of ECMP with the candidate molecules.

All publications and patents mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described method and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit
20 of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION

- (i) APPLICANT: INCYTE PHARMACEUTICALS, INC.
- (ii) TITLE OF THE INVENTION: HUMAN EXTRACELLULAR MATRIX PROTEINS
- (iii) NUMBER OF SEQUENCES: 6
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Incyte Pharmaceuticals, Inc.
 - (B) STREET: 3174 Porter Drive
 - (C) CITY: Palo Alto
 - (D) STATE: CA
 - (E) COUNTRY: USA
 - (F) ZIP: 94304
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Diskette
 - (B) COMPUTER: IBM Compatible
 - (C) OPERATING SYSTEM: DOS
 - (D) SOFTWARE: FastSEQ for Windows Version 2.0
- (vi) CURRENT APPLICATION DATA:
 - (A) PCT APPLICATION NUMBER: To Be Assigned
 - (B) FILING DATE: Herewith
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) U. S. APPLICATION NUMBER: 08/884,072
 - (B) FILING DATE: 27 June 1997
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Billings, Lucy J.
 - (B) REGISTRATION NUMBER: 36,749
 - (C) REFERENCE/DOCKET NUMBER: PF-0333 PCT
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 650-855-0555
 - (B) TELEFAX: 650-845-4166
 - (C) TELEX:

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 448 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (vii) IMMEDIATE SOURCE:
 - (A) LIBRARY: CORNNOT01
 - (B) CLONE: 45517
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

Met Pro Gly Ile Lys Arg Ile Leu Thr Val Thr Ile Leu Ala Leu Cys
1           5           10          15
Leu Pro Ser Pro Gly Asn Ala Gln Ala Gln Cys Thr Asn Gly Phe Asp
20          25          30
Leu Asp Arg Gln Ser Gly Gln Cys Leu Asp Ile Asp Glu Cys Arg Thr
35          40          45
Ile Pro Glu Ala Cys Arg Gly Asp Met Met Cys Val Asn Gln Asn Gly

```

50	55	60													
Gly	Tyr	Leu	Cys	Ile	Pro	Arg	Thr	Asn	Pro	Val	Tyr	Arg	Gly	Pro	Tyr
65					70				75						80
Ser	Asn	Pro	Tyr	Ser	Thr	Pro	Tyr	Ser	Gly	Pro	Tyr	Pro	Ala	Ala	
															95
85								90							
Pro	Pro	Leu	Ser	Ala	Pro	Asn	Tyr	Pro	Thr	Ile	Ser	Arg	Pro	Leu	Ile
								105							110
100															
Cys	Arg	Phe	Gly	Tyr	Gln	Met	Asp	Glu	Ser	Asn	Gln	Cys	Val	Asp	Val
								120							125
115															
Asp	Glu	Cys	Ala	Thr	Asp	Ser	His	Gln	Cys	Asn	Pro	Thr	Gln	Ile	Cys
								135							140
130															
Ile	Asn	Thr	Glu	Gly	Gly	Tyr	Thr	Cys	Ser	Cys	Thr	Asp	Gly	Tyr	Trp
															160
145					150				155						
Leu	Leu	Glu	Gly	Gln	Cys	Leu	Asp	Ile	Asp	Glu	Cys	Arg	Tyr	Gly	Tyr
															175
165								170							
Cys	Gln	Gln	Leu	Cys	Ala	Asn	Val	Pro	Gly	Ser	Tyr	Ser	Cys	Thr	Cys
								180		185					190
180															
Asn	Pro	Gly	Phe	Thr	Leu	Asn	Glu	Asp	Gly	Arg	Ser	Cys	Gln	Asp	Val
								195		200					205
195															
Asn	Glu	Cys	Ala	Thr	Glu	Asn	Pro	Cys	Val	Gln	Thr	Cys	Val	Asn	Thr
								210		215					220
210															
Tyr	Gly	Ser	Phe	Ile	Cys	Arg	Cys	Asp	Pro	Gly	Tyr	Glu	Leu	Glu	
								225		230		235			240
225															
Asp	Gly	Val	His	Cys	Ser	Asp	Met	Asp	Glu	Cys	Ser	Phe	Ser	Glu	Phe
								245		250					255
245															
Leu	Cys	Gln	His	Glu	Cys	Val	Asn	Gln	Pro	Gly	Thr	Tyr	Phe	Cys	Ser
								260		265					270
260															
Cys	Pro	Pro	Gly	Tyr	Ile	Leu	Leu	Asp	Asp	Asn	Arg	Ser	Cys	Gln	Asp
								275		280					285
275															
Ile	Asn	Glu	Cys	Glu	His	Arg	Asn	His	Thr	Cys	Asn	Leu	Gln	Gln	Thr
								290		295		300			
290															
Cys	Tyr	Asn	Leu	Gln	Gly	Gly	Phe	Lys	Cys	Ile	Asp	Pro	Ile	Arg	Cys
								305		310		315			320
305															
Glu	Glu	Pro	Tyr	Leu	Arg	Ile	Ser	Asp	Asn	Arg	Cys	Met	Cys	Pro	Ala
								325		330					335
325															
Glu	Asn	Pro	Gly	Cys	Arg	Asp	Gln	Pro	Phe	Thr	Ile	Leu	Tyr	Arg	Asp
								340		345					350
340															
Met	Asp	Val	Val	Ser	Gly	Arg	Ser	Val	Pro	Ala	Asp	Ile	Phe	Gln	Met
								355		360		365			
355															
Gln	Ala	Thr	Thr	Arg	Tyr	Pro	Gly	Ala	Tyr	Tyr	Ile	Phe	Gln	Ile	Lys
								370		375		380			
370															
Ser	Gly	Asn	Glu	Gly	Arg	Glu	Phe	Tyr	Met	Arg	Gln	Thr	Gly	Pro	Ile
								385		390		395			400
385															
Ser	Ala	Thr	Leu	Val	Met	Thr	Arg	Pro	Ile	Lys	Gly	Pro	Arg	Glu	Ile
								405		410					415
405															
Gln	Leu	Asp	Leu	Glu	Met	Ile	Thr	Val	Asn	Thr	Val	Ile	Asn	Phe	Arg
								420		425					430
420															
Gly	Ser	Ser	Val	Ile	Arg	Leu	Arg	Ile	Tyr	Val	Ser	Gln	Tyr	Pro	Phe
								435		440					445

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2550 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: CORNNOT01
- (B) CLONE: 45517

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

CCAAGATTGT TGTGAGGAGT CTAGCCAGTT GGTGAGCGCT GTAATCTGAA CCAGCTGTGT

60

CCAGACTGAG	GCCCCATTTG	CATTATTTAA	CATACTTAGA	AAATGAAGTG	TTCATTTTA	120
ACATTCCTCC	TCCAATTGGT	TTAATGCTGA	ATTACTGAAG	AGGGCTAACG	AAAACCAGGT	180
GCTTGCCTG	AGGGCTCTGC	AGTGGCTGGG	AGGACCCCGG	CGCTCTCCCC	GTGTCCTCTC	240
CAAGACTCGC	TCGGCCCCCTC	TGGAATAAAA	CACCCGCGAG	CCCCGAGGGC	CCAGAGGAGG	300
CCGACGTGCC	CGAGCTCTC	CGGGGGTCCC	GCCCCGCGAGC	TTTCTCTCG	CCTTCGCATC	360
TCCTCCCTCG	CGCTCTTGG	CATGCCAGGA	ATAAAAAGGA	TACTCACTGT	TACCATTCTG	420
GCTCTCTGTC	TTCCAAGCCC	TGGGAATGCA	CAGGCACAGT	GCACGAATGG	CTTGACCTG	480
GATCGCCAGT	CAGGACAGTG	TTTAGATATT	GATGAATGCC	GAACCATCCC	CGAGGCCTGC	540
CGAGGAGACA	TGATGTGTGT	TAACCAAAAT	GGCGGGTATT	TATGCATTCC	CCGGACAAAC	600
CCTGTGTATC	GAGGGCCCTA	CTCGAACCCC	TACTCGACCC	CCTACTCAGG	TCCGTACCCA	660
GCAGCTGCC	CACCACTCTC	AGCTCCAAAC	TATCCCACGA	TCTCCAGGCC	TCTTATATGC	720
CGCTTGGAT	ACCAAGATGGA	TGAAAGCAAC	CAATGTGTGG	ATGTGGACGA	GTGTGCAACA	780
GATTCCCACC	AGTGCAACCC	CACCCAGATC	TGCATCAATA	CTGAAGGGCGG	GTACACCTGC	840
TCCTGCACCG	ACGGATATTG	GCTTCTGGAA	GGCCAGTGT	TAGACATTGA	TGAATGTGGC	900
TATGGTTACT	GCCAGCAGCT	CTGTGCGAAT	GTTCTGGAT	CCTATTCTTG	TACATGCAAC	960
CCTGGTTTTA	CCCTCAATGA	GGATGGAAGG	TCTTGCCAAG	ATGTGAACGA	GTGTGCCACC	1020
GAGAACCCCT	CGGTGCAAAC	CTGCGTCAAC	ACCTACGGCT	CTTTCATCTG	CCGCTGTGAC	1080
CCAGGATATG	AACTTGAGGA	AGATGGCGTT	CATTGCACTG	ATATGGACGA	GTGCAGCTTC	1140
TCTGAGTTCC	TCTGCCAAC	TGAGTGTGTG	AACCAGCCCC	GCACATACATT	CTGCTCCTGC	1200
CCTCCAGGCT	ACATCCTGCT	GGATGACAAC	CGAAGCTGCC	AAGACATCAA	CGAATGTGAG	1260
CACAGGAACC	ACACGTGCAA	CCTGCAGCAG	ACGTGCTACA	ATTTACAAGG	GGGCTTCAA	1320
TGCATCGACC	CCATCCGCTC	TGAGGAGCCT	TATCTGAGGA	TCAGTGATAA	CCGCTGTATG	1380
TGTCCTGCTG	AGAACCCCTGG	CTGCAGAGAC	CAGCCCTTTA	CCATCTTGTA	CCGGGACATG	1440
GACGTGGTGT	CAGGACGCTC	CGTCTCCCGCT	GACATCTTCC	AAATGCAAGC	CACGACCCGC	1500
TACCCCTGGGG	CCTATTACAT	TTTCCAGATC	AAATCTGGGA	ATGAGGGCAG	AGAATTTTAC	1560
ATGCGCCAAA	CGGGCCCCAT	CAGTGCCACC	CTGGTGTGAA	CACGCCCCAT	CAAAGGGCCC	1620
CGGGAAATCC	AGCTGGACTT	GGAAATGATC	ACTGTCAACA	CTGTCACTAA	CTTCAGAGGC	1680
AGCTCCGTGA	TCCGACTGCG	GATATATGTG	TCGCAGTACC	CATTCTGAGC	CTCAGGCTGG	1740
AGCCTCCGAC	GCTGCCTCTC	ATTGGCACCA	AGGGACAGGA	GAAGAGAGGA	ATAAACAGAG	1800
AGAATGAGAG	CGACACAGAC	GTTAGGCATT	TCCTGCTGAA	CGTTTCCCCG	AAGAGTCAGC	1860
CCCGACTTCC	TGACTCTCAC	CTGTACTATT	GCAGACCTGT	CACCCGTGAG	GACTTGCCAC	1920
CCCCAGTCC	TATGACACAG	TTATCAAAAA	GTATTATCAT	TGCTCCCCCTG	ATAGAAGATT	1980
GTTGGTGAAT	TTTCAGGCC	TTCAAGTTAT	TTCCACTATT	TTCAAAGAAA	ATAGATTAGG	2040
TTTGGGGGGG	TCTGAGTCTA	TGTTCAAAGA	CTGTGAACAG	CTTGCTGTCA	CTTCTTCACC	2100
TCTTCCACTC	CTTCTCTCAC	TGTGTTACTG	CTTGTCAAAG	ACCCGGGAGC	TGGCGGGGAA	2160
CCCTGGGAGT	AGCTAGTTG	CTTTTGGCT	ACACAGAGAA	GGCTATGTAA	ACAAACCACA	2220
GCAGGATCGA	AGGGTTTTA	GAGAATGTGT	TTCAAAACCA	TGCCTGGTAT	TTTCAACCAT	2280
AAAAGAAGTT	TCAGTTGTCC	TTAAATTGT	ATAACGGTT	AATTCTGTCT	TGTTCATTTT	2340
GAGTATTTT	AAAAAAATATG	TCGTAGAATT	CCTTCGAAAG	GCCTTCAGAC	ACATGCTATG	2400
TTCTGTCTTC	CCAAACCCAG	TCTCCTCTCC	ATTTTAGCCC	AGTGTGTTCT	TTGAGGACCC	2460
CTTAATCTTG	CTTTCTTAG	AATTTTACC	CAATTGGATT	GGAATGCAGA	GGTCTCCAAA	2520
CTGATTAAT	ATTGAAGAG	AAAAAAA				2550

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 540 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: BRAITUT13
- (B) CLONE: 1621777

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met	Gly	Thr	Thr	Ala	Arg	Ala	Ala	Leu	Val	Leu	Thr	Tyr	Leu	Ala	Val
1				5				10					15		
Ala	Ser	Ala	Ala	Ser	Glu	Gly	Gly	Phe	Thr	Ala	Thr	Gly	Gln	Arg	Gln
					20			25					30		
Leu	Arg	Pro	Glu	His	Phe	Gln	Glu	Val	Gly	Tyr	Ala	Ala	Pro	Pro	Ser
					35			40					45		
Pro	Pro	Leu	Ser	Arg	Ser	Leu	Pro	Met	Asp	His	Pro	Asp	Ser	Ser	Gln
						55				60					

His	Gly	Pro	Pro	Phe	Glu	Gly	Gln	Ser	Gln	Val	Gln	Pro	Pro	Pro	Ser
65				70					75					80	
Gln	Glu	Ala	Thr	Pro	Leu	Gln	Glu	Lys	Leu	Leu	Pro	Ala	Gln	Leu	
				85				90					95		
Pro	Ala	Glu	Lys	Glu	Val	Gly	Pro	Pro	Leu	Pro	Gln	Glu	Ala	Val	Pro
				100				105					110		
Leu	Gln	Lys	Glu	Leu	Pro	Ser	Leu	Gln	His	Pro	Asn	Glu	Gln	Lys	Glu
				115			120					125			
Gly	Met	Pro	Ala	Pro	Phe	Gly	Asp	Gln	Ser	His	Pro	Glu	Pro	Glu	Ser
	130				135				140						
Trp	Asn	Ala	Ala	Gln	His	Cys	Gln	Gln	Asp	Arg	Ser	Gln	Gly	Gly	Trp
	145				150				155				160		
Gly	His	Arg	Leu	Asp	Gly	Phe	Pro	Pro	Gly	Arg	Pro	Ser	Pro	Asp	Asn
				165				170					175		
Leu	Asn	Gln	Ile	Cys	Leu	Pro	Asn	Arg	Gln	His	Val	Val	Tyr	Gly	Pro
				180			185					190			
Trp	Asn	Leu	Pro	Gln	Ser	Ser	Tyr	Ser	His	Leu	Thr	Arg	Gln	Gly	Glu
	195				200			205							
Thr	Leu	Asn	Phe	Leu	Glu	Ile	Gly	Tyr	Ser	Arg	Cys	Cys	His	Cys	Arg
	210				215				220						
Ser	His	Thr	Asn	Arg	Leu	Glu	Cys	Ala	Lys	Leu	Val	Trp	Glu	Glu	Ala
	225				230				235				240		
Met	Ser	Arg	Phe	Cys	Glu	Ala	Glu	Phe	Ser	Val	Lys	Thr	Arg	Pro	His
				245				250					255		
Trp	Cys	Cys	Thr	Arg	Gln	Gly	Glu	Ala	Arg	Phe	Ser	Cys	Phe	Gln	Glu
				260			265				270				
Glu	Ala	Pro	Gln	Pro	His	Tyr	Gln	Leu	Arg	Ala	Cys	Pro	Ser	His	Gln
	275				280				285						
Pro	Asp	Ile	Ser	Ser	Gly	Leu	Glu	Leu	Pro	Phe	Pro	Pro	Gly	Val	Pro
	290				295				300						
Thr	Leu	Asp	Asn	Ile	Lys	Asn	Ile	Cys	His	Leu	Arg	Arg	Phe	Arg	Ser
	305				310				315				320		
Val	Pro	Arg	Asn	Leu	Pro	Ala	Thr	Asp	Pro	Leu	Gln	Arg	Glu	Leu	Leu
				325				330					335		
Ala	Leu	Ile	Gln	Leu	Glu	Arg	Glu	Phe	Gln	Arg	Cys	Cys	Arg	Gln	Gly
				340			345					350			
Asn	Asn	His	Thr	Cys	Thr	Trp	Lys	Ala	Trp	Glu	Asp	Thr	Leu	Asp	Lys
				355			360				365				
Tyr	Cys	Asp	Arg	Glu	Tyr	Ala	Val	Lys	Thr	His	His	His	Leu	Cys	Cys
				370			375				380				
Arg	His	Pro	Pro	Ser	Pro	Thr	Arg	Asp	Glu	Cys	Phe	Ala	Arg	Arg	Ala
	385				390				395				400		
Pro	Tyr	Pro	Asn	Tyr	Asp	Arg	Asp	Ile	Leu	Thr	Ile	Asp	Ile	Gly	Arg
				405			410					415			
Val	Thr	Pro	Asn	Leu	Met	Gly	His	Leu	Cys	Gly	Asn	Gln	Arg	Val	Leu
				420				425				430			

Thr	Lys	His	Lys	His	Ile	Pro	Gly	Leu	Ile	His	Asn	Met	Thr	Ala	Arg
435						440						445			
Cys	Cys	Asp	Leu	Pro	Phe	Pro	Glu	Gln	Ala	Cys	Cys	Ala	Glu	Glu	Glu
450						455						460			
Lys	Leu	Thr	Phe	Ile	Asn	Asp	Leu	Cys	Gly	Pro	Arg	Arg	Asn	Ile	Trp
465						470					475				480
Arg	Asp	Pro	Ala	Leu	Cys	Cys	Tyr	Leu	Ser	Pro	Gly	Asp	Glu	Gln	Val
											485			495	
Asn	Cys	Phe	Asn	Ile	Asn	Tyr	Leu	Arg	Asn	Val	Ala	Leu	Val	Ser	Gly
										500		505		510	
Asp	Thr	Glu	Asn	Ala	Lys	Gly	Gln	Gly	Glu	Gln	Gly	Ser	Thr	Gly	Gly
										515		520		525	
Thr	Asn	Ile	Ser	Ser	Thr	Ser	Glu	Pro	Lys	Glu	Glu				
							530			535			540		

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1899 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: BRAITUT13
- (B) CLONE: 162177

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

TGGGTGCAAG	CTCACAAACCG	TAACAGCCAC	CAGACAAGCT	TCAGTGGCCG	GCCCTTCACA	60
TCCAGACTTG	CCTGAGAGGA	CCCACCTCTG	AGTGTCCAGT	GGTCAGTTGC	CCCAGGATGG	120
GGACACACAGC	CAGAGCAGCC	TTGGTCTTGA	CCTATTGTC	TGTTGCTTCT	GCTGCCTCTG	180
AGGGAGGCTT	CACGGCTACA	GGACAGAGGC	AGCTGAGGCC	AGAGCACTTT	CAAGAAGTTG	240
GCTACGGCAGC	TCCCCCTCTC	CCACCCCTAT	CCCGAAGCCT	CCCCATGGAT	CACCCCTGACT	300
CCTCTCAGCA	TGGCCCTCCC	TTTGAGGGAC	AGAGTCAGT	GCAGCCCCCT	CCCTCTCAGG	360
AGGCCACCCCC	TCTCCAACAG	GAAAAGCTGC	TACCTGCCA	ACTCCCTGCT	GAAAAGGAAG	420
TGGGTCCCCC	TCTCCCTCAG	GAAGCTGTCC	CCCTCCAAA	AGAGCTGCC	TCTCTCCAGC	480
ACCCCAATGA	ACAGAAGGAA	GGAATGCCAG	CTCCATTGTC	GGACCAAGAGC	CATCCAGAAC	540
CTGAGTCCTG	GAATGCAGCC	CAGCACTGCC	AACAGGACCG	GTCACCAAGGG	GGCTGGGGCC	600
ACCGGCTGGA	TGGCTCCCC	CCTGGCGGGC	CTTCTCCAGA	CAATCTGAAC	CAAATCTGCC	660
TTCCTAACCG	TCAGCATGTG	GTATATGGTC	CCTGGAACTC	ACACAGTCC	AGCTACTCCC	720
ACCTCACTCG	CCAGGGTGTAG	ACCCCTCAATT	TCCTGGAGAT	TGGATATTCC	CGCTGCTGCC	780
ACTGCCGCG	CCACACAAAC	CGCCTAGAGT	GTGCCAAACT	TGTGTGGGAG	GAAGCAATGA	840
GCCGATTCTG	TGAGGCGCAG	TTCTCGGTCA	AGACCCGACC	CCACTGGTGC	TGCACGCGGC	900
AGGGGGAGGC	TCGGTTCTCC	TGCTTCCAGG	AGGAAGCTCC	CCAGCCACAC	TACCAGCTCC	960
GGGCTGCC	CAGCCATCAG	CCTGATATTTC	CCTCGGGTCT	TGAGCTGCCT	TTCCCTCCTG	1020
GGGTGCCAAC	ATTGGACAAT	ATCAAGAACAA	TCTGCCACCT	GAGGCGCTTC	CGCTCTGTGC	1080
CACGCAACCT	GGCAGCTACT	GACCCCTAC	AAAGGGAGCT	GCTGGCACTG	ATCCAGCTGG	1140
AGAGGGAGTT	CCAGCGCTGC	TGCCCGCAGG	GGAAACAATCA	CACCTGTACA	TGGAAGGCCT	1200
GGGAGGATAC	CCTTGACAAA	TACTGTGACC	GGGAGTATGC	TGTGAAGACC	CACCACCACT	1260
TGTGTTGCCG	CCACCCCTCCC	AGCCCTACTC	GGGATGAGTG	CTTTGCCCGT	GGGGCTCCTT	1320
ACCCCAACTA	TGACCGGGAC	ATCTTGACCA	TTGACATCGG	TCGAGTCACC	CCCAACCTCA	1380
TGGGCCACCT	CTGTGGAAAC	CAAAGAGTTC	TCACCAAGCA	TAAACATATT	CCTGGGCTGA	1440
TCCACAAACAT	GACTGCCGC	TGCTGTGACC	TGCCATTTC	AGAACAGGCC	TGCTGTGCAG	1500
AGGAGGAGAA	ATTAACCTTC	ATCAATGATC	TGTGTGGTCC	CCGACGTAAC	ATCTGGCCAG	1560
ACCCTGCCCT	CTGCTGTTAC	CTGAGTCCTG	GGGATGAACA	GGTCAACTGC	TTCAACATCA	1620
ATTATCTGAG	GAACGTGGCT	CTAGTGTCTG	GAGACACTGA	GAACGCCAAG	GGCCAGGGGG	1680
AGCAGGGCTC	AACTGGAGGA	ACAAATATCA	GCTCCACCTC	TGAGCCCAAG	GAAGAATGAG	1740
TCACCCCAAGA	GCCCTAGAGG	GTCAGATGGG	GGGAACCCCA	CCCTGCCCA	CCCACATCTGAA	1800
CACTCATTAC	ACTAAACACC	TCTTGATTT	GGTGTCTCA	TTGTCTATCT	AATGTCTCAC	1860
CCGCAGTGT	TTAAGTGGAT	CTTGGTGCC	TGGCCCAAGG			1899

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 387 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:
 (A) LIBRARY: GenBank
 (B) CLONE: 458228

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Met Ala Thr Ser Gly Val Leu Pro Gly Gly Phe Val Ala Ser Ala
 1 5 10 15
 Ala Ala Val Ala Gly Pro Glu Met Gln Thr Gly Arg Asn Asn Phe Val
 20 25 30
 Ile Arg Arg Asn Pro Ala Asp Pro Gln Arg Ile Pro Ser Asn Pro Ser
 35 40 45
 His Arg Ile Gln Cys Ala Ala Gly Tyr Glu Gln Ser Glu His Asn Val
 50 55 60
 Cys Gln Asp Ile Asp Glu Cys Thr Ala Gly Thr His Asn Cys Arg Ala
 65 70 75 80
 Asp Gln Val Cys Ile Asn Leu Arg Gly Ser Phe Ala Cys Gln Cys Pro
 85 90 95
 Pro Gly Tyr Gln Lys Arg Gly Glu Gln Cys Val Asp Ile Asp Glu Cys
 100 105 110
 Thr Ile Pro Pro Tyr Cys His Gln Arg Cys Val Asn Thr Pro Gly Ser
 115 120 125
 Phe Tyr Cys Gln Cys Ser Pro Gly Phe Gln Leu Ala Ala Asn Asn Tyr
 130 135 140
 Thr Cys Val Asp Ile Asn Glu Cys Asp Ala Ser Asn Gln Cys Ala Gln
 145 150 155 160
 Gln Cys Tyr Asn Ile Leu Gly Ser Phe Ile Cys Gln Cys Asn Gln Gly
 165 170 175
 Tyr Glu Leu Ser Ser Asp Arg Leu Asn Cys Glu Asp Ile Asp Glu Cys
 180 185 190
 Arg Thr Ser Ser Tyr Leu Cys Gln Tyr Gln Cys Val Asn Glu Pro Gly
 195 200 205
 Lys Phe Ser Cys Met Cys Pro Gln Gly Tyr Gln Val Val Arg Ser Arg
 210 215 220
 Thr Cys Gln Asp Ile Asn Glu Cys Glu Thr Thr Asn Glu Cys Arg Glu
 225 230 235 240
 Asp Glu Met Cys Trp Asn Tyr His Gly Gly Phe Arg Cys Tyr Pro Arg
 245 250 255
 Asn Pro Cys Gln Asp Pro Tyr Ile Leu Thr Pro Glu Asn Arg Cys Val
 260 265 270
 Cys Pro Val Ser Asn Ala Met Cys Arg Glu Leu Pro Gln Ser Ile Val
 275 280 285
 Tyr Lys Tyr Met Ser Ile Arg Ser Asp Arg Ser Val Pro Ser Asp Ile
 290 295 300
 Phe Gln Ile Gln Ala Thr Thr Ile Tyr Ala Asn Thr Ile Asn Thr Phe
 305 310 315 320
 Arg Ile Lys Ser Gly Asn Glu Asn Gly Glu Phe Tyr Leu Arg Gln Thr
 325 330 335
 Ser Pro Val Ser Ala Met Leu Val Leu Val Lys Ser Leu Ser Gly Pro
 340 345 350
 Arg Glu His Ile Val Asp Leu Glu Met Leu Thr Val Ser Ser Ile Gly
 355 360 365

Thr	Phe	Arg	Thr	Ser	Ser	Val	Leu	Arg	Leu	Thr	Ile	Ile	Val	Gly	Pro
370						375						380			
Phe	Ser	Phe													
385															

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 559 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vii) IMMEDIATE SOURCE:

- (A) LIBRARY: GenBank
- (B) CLONE: 496120

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met	Gly	Thr	Val	Ser	Arg	Ala	Ala	Leu	Ile	Leu	Ala	Cys	Leu	Ala	Leu
1						5			10			15			
Ala	Ser	Ala	Ala	Ser	Glu	Gly	Ala	Phe	Lys	Ala	Ser	Asp	Gln	Arg	Glu
						20			25			30			
Met	Thr	Pro	Glu	Arg	Leu	Phe	Gln	His	Leu	His	Glu	Val	Gly	Tyr	Ala
						35			40			45			
Ala	Pro	Pro	Ser	Leu	Pro	Gln	Thr	Arg	Arg	Leu	Arg	Val	Asp	His	Ser
						50			55			60			
Val	Thr	Ser	Leu	His	Asp	Pro	Pro	Leu	Phe	Glu	Glu	Gln	Arg	Glu	Val
						65			70			75			80
Gln	Pro	Pro	Ser	Ser	Pro	Glu	Asp	Ile	Pro	Val	Tyr	Glu	Glu	Asp	Trp
						85			90			95			
Pro	Thr	Phe	Leu	Asn	Pro	Asn	Val	Asp	Lys	Ala	Gly	Pro	Ala	Val	Pro
						100			105			110			
Gln	Glu	Ala	Ile	Pro	Leu	Gln	Lys	Glu	Gln	Pro	Pro	Pro	Gln	Val	His
						115			120			125			
Ile	Glu	Gln	Lys	Glu	Ile	Asp	Pro	Pro	Ala	Gln	Pro	Gln	Glu	Glu	Ile
						130			135			140			
Val	Gln	Lys	Glu	Val	Lys	Pro	His	Thr	Leu	Ala	Gly	Gln	Leu	Pro	Pro
						145			150			155			160
Glu	Pro	Arg	Thr	Trp	Asn	Pro	Ala	Arg	His	Cys	Gln	Gln	Gly	Arg	Arg
						165			170			175			
Gly	Val	Trp	Gly	His	Arg	Leu	Asp	Gly	Phe	Pro	Pro	Gly	Arg	Pro	Ser
						180			185			190			
Pro	Asp	Asn	Leu	Lys	Gln	Ile	Cys	Leu	Pro	Glu	Arg	Gln	His	Val	Ile
						195			200			205			
Tyr	Gly	Pro	Trp	Asn	Leu	Pro	Gln	Thr	Gly	Tyr	Ser	His	Leu	Ser	Arg
						210			215			220			
Gln	Gly	Glu	Thr	Leu	Asn	Val	Leu	Glu	Thr	Gly	Tyr	Ser	Arg	Cys	Cys
						225			230			235			240
Pro	Cys	Arg	Ser	Asp	Thr	Asn	Arg	Leu	Asp	Cys	Leu	Lys	Leu	Val	Trp
						245			250			255			
Glu	Asp	Ala	Met	Thr	Gln	Phe	Cys	Glu	Ala	Glu	Phe	Ser	Val	Lys	Thr
						260			265			270			
Arg	Pro	His	Leu	Cys	Cys	Arg	Leu	Arg	Gly	Glu	Glu	Arg	Phe	Ser	Cys
						275			280			285			
Phe	Gln	Lys	Glu	Ala	Pro	Arg	Pro	Asp	Tyr	Leu	Leu	Arg	Pro	Cys	Pro
						290			295			300			
Val	His	Gln	Asn	Gly	Met	Ser	Ser	Gly	Pro	Gln	Leu	Pro	Phe	Pro	Pro
						305			310			315			320
Gly	Leu	Pro	Thr	Pro	Asp	Asn	Val	Lys	Asn	Ile	Cys	Leu	Leu	Arg	Arg
						325			330			335			
Phe	Arg	Ala	Val	Pro	Arg	Asn	Leu	Pro	Ala	Thr	Asp	Ala	Ile	Gln	Arg
						340			345			350			
Gln	Leu	Gln	Ala	Leu	Thr	Arg	Leu	Glu	Thr	Glu	Phe	Gln	Arg	Cys	Cys
						355			360			365			

Arg Gln Gly His Asn His Thr Cys Thr Trp Lys Ala Trp Glu Gly Thr
370 375 380
Leu Asp Gly Tyr Cys Glu Arg Glu Leu Ala Ile Lys Thr His Pro His
385 390 395 400
Ser Cys Cys His Tyr Pro Pro Ser Pro Ala Arg Asp Glu Cys Phe Ala
405 410 415
His Leu Ala Pro Tyr Pro Asn Tyr Asp Arg Asp Ile Leu Thr Leu Asp
420 425 430
Leu Ser Arg Val Thr Pro Asn Leu Met Gly Gln Leu Cys Gly Ser Gly
435 440 445
Arg Val Leu Ser Lys His Lys Gln Ile Pro Gly Leu Ile Gln Asn Met
450 455 460
Thr Val Arg Cys Cys Glu Leu Pro Tyr Pro Glu Gln Ala Cys Cys Gly
465 470 475 480
Glu Glu Glu Lys Leu Ala Phe Ile Glu Asn Leu Cys Gly Pro Arg Arg
485 490 495
Asn Ser Trp Lys Asp Pro Ala Leu Cys Cys Asp Leu Ser Pro Glu Asp
500 505 510
Lys Gln Ile Asn Cys Phe Asn Thr Asn Tyr Leu Arg Asn Val Ala Leu
515 520 525
Val Ala Gly Asp Thr Gly Asn Ala Thr Gly Leu Gly Glu Gln Gly Pro
530 535 540
Thr Arg Gly Thr Asp Ala Asn Pro Ala Pro Gly Ser Lys Glu Glu
545 550 555

What is claimed is:

1. An isolated and purified polynucleotide encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:1.
- 5 2. An isolated and purified polynucleotide which is fully complementary to the polynucleotide of claim 1.
3. An isolated and purified polynucleotide consisting of SEQ ID NO:2.
- 10 4. An isolated and purified polynucleotide which is fully complementary to the polynucleotide sequence of claim 3.
5. An expression vector containing the polynucleotide of claim 1.
- 15 6. A host cell containing the expression vector of claim 5.
7. A method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:1, the method comprising the steps of:
 - 20 a) culturing the host cell of claim 6 under conditions suitable for the expression of the polypeptide; and
 - b) recovering the polypeptide from the host cell culture.

1/17

CCA	AGA	TTG	TGA	GGA	GTC	TAG	CCA	GTT	GGT	GAG	CGC	TGT	AAT	CTG	AAC	CAG	
63		72		81			90			99				99		108	
CTG	TGT	CCA	GAC	TGA	GGC	CCC	ATT	TGC	ATT	ATT	TAA	CAT	ACT	TAG	AAA	ATG	AAG
117		126		135			144			153				153		162	
TGT	TCA	TTT	TTA	ACA	TTC	CTC	CTC	CAA	TTG	GTT	TAA	TGC	TGA	ATT	ACT	GAA	GAG
171		180		189			198			198				198		216	
GGC	TAA	GCA	AAA	CCA	GGT	GCT	TGC	GCT	GAG	GGC	TCT	GCA	GTG	GCT	GGG	AGG	ACC
225		234		243			252			252				261		270	
CCG	GGG	CTC	TCC	CCG	TGT	CCT	CTC	CAC	GAC	TCG	CTC	GGC	CCC	TCT	GGA	ATA	AAA
279		288		297			306			306				315		324	
CAC	CCG	CGA	GCC	CGC	AGG	GCC	CAG	AGG	CCG	ACG	TGC	CCG	AGC	TCC	TCC	GGG	
333		342		351			360			360				369		378	
GGT	CCC	GCC	GGC	GAG	CTT	TCT	CGC	CTT	CGC	ATC	TCC	TCC	TCC	CGC	GTC	TTC	
387		396		405			414			414				423		432	
GAC	ATG	CCA	GGA	ATA	AAA	AGG	ATA	CTC	ACT	GTT	ACC	ATT	CTG	GCT	CTC	TGT	CTT
M	P	G	I	K	R	I	L	T	V	T	I	L	A	L	C	L	

FIGURE 1A

2/17

CCA	AGC	CCT	GGG	AAT	GCA	CAG	GCA	CAG	TGC	ACG	AAT	GGC	TTT	GAC	CTG	GAT	CGC
P	S	P	G	N	A	Q	A	Q	C	T	N	G	F	D	L	D	R
Q	S	G	Q	C	L	D	I	D	E	C	R	T	I	P	E	A	C
441		450		459		468		468		477		477		486			
CAG	TCA	GGA	CAG	TGT	TTA	GAT	ATT	GAT	GAA	TGC	CGA	ACC	ATC	CCC	GAG	GCC	TGC
R	G	D	M	M	C	V	N	Q	N	G	G	Y	L	C	I	P	R
495		504		513		522		522		531		531		540			
CGA	GGA	GAC	ATG	ATG	TGT	GTT	AAC	CAA	AAT	GGC	GGG	TAT	TTA	TGC	ATT	CCC	CGG
603		612		621		630		630		639		639		648			
ACA	AAC	CCT	GTG	TAT	CGA	GGG	CCC	TAC	TGC	AAC	CCC	TAC	TCG	ACC	CCC	TAC	TCA
T	N	P	V	Y	R	G	P	Y	S	N	P	Y	S	T	P	Y	S
657		666		675		684		684		693		693		702			
GGT	CCG	TAC	CCA	GCA	GCT	GCC	CCA	CTC	TCA	GCT	CCA	AAC	TAT	CCC	ACG	ATC	
G	P	Y	P	A	A	P	P	L	S	A	P	N	Y	P	T	I	
711		720		729		738		738		747		747		756			
TCC	AGG	CCT	CTT	ATA	TGC	CGC	TTT	GGA	TAC	CAG	ATG	GAT	GAA	AGC	AAC	CAA	TGT
S	R	P	L	I	C	R	F	G	Y	Q	M	D	E	S	N	Q	C
765		774		783		792		792		801		801		810			
GTG	GAT	GTG	GAC	GAG	TGT	GCA	ACA	GAT	TCC	CAC	CAG	TGC	AAC	CCC	ACC	CAG	ATC
V	D	V	D	E	C	A	T	D	S	H	Q	C	N	P	T	Q	I

FIGURE 1B

3/17

FIGURE 1C

1197	TTC	TGC	TCC	TGC	CCT	CCA	GGC	TAC	ATC	CTG	CTG	GAT	GAC	AAC	CGA	AGC	TGC	CAA	1242
F	C	S	C	P	P	G	Y	I	L	L	D	D	N	R	S	C	C	Q	
1251	GAC	ATC	AAC	GAA	TGT	GAG	CAC	AGG	AAC	CAC	ACG	TGC	AAC	CTG	CAG	CAG	ACG	TGC	1296
D	I	N	E	C	E	H	R	N	H	T	C	N	L	Q	Q	T	C		
1305	TAC	AAT	TTA	CAA	GGG	GGC	TTC	AAA	TGC	ATC	GAC	CCC	ATC	CGC	TGT	GAG	GAG	CCT	1350
Y	N	L	Q	G	G	F	K	C	I	D	P	I	R	C	E	E	P		
1359	TAT	CTG	AGG	ATC	AGT	GAT	AAC	CGC	TGT	ATG	TGT	CCT	GCT	GAG	AAC	CCT	GGC	TGC	1404
Y	L	R	I	S	D	N	R	C	M	C	P	A	E	N	P	G	C		
1413	AGA	GAC	CAG	CCC	TTT	ACC	ATC	TTC	TAC	CGG	GAC	ATG	GAC	GTG	GTG	TCA	GGA	CGC	1458
R	D	Q	P	F	T	I	L	Y	R	D	M	D	V	V	S	G	R		
1467	TCC	GTT	CCC	GCT	GAC	ATC	TTC	CAA	ATG	CAA	GCC	ACG	ACC	CGC	TAC	CCT	GGG	GCC	1512
S	V	P	A	D	I	F	Q	M	Q	A	T	T	R	Y	P	G	A		
1521	TAT	TAC	ATT	TTC	CAG	ATC	AAA	TCT	GGG	AAT	GAG	GGC	AGA	GAA	TTT	TAC	ATG	CGG	1566
Y	Y	I	F	Q	I	K	S	G	N	E	G	R	E	F	Y	M	R		

FIGURE 1D

5/17

CAA	ACG	GGC	CCC	ATC	AGT	GCC	ACC	CTG	GTG	ATG	ACA	CGC	CCC	ATC	AAA	GGG	CCC
Q	T	G	P	I	S	A	T	L	V	M	T	R	P	I	K	G	P
1629	1638	1647	1656	1665	1674												
CGG	GAA	ATC	CAG	CTG	GAC	TTG	GAA	ATG	ATC	ACT	GTC	AAC	ACT	GTC	ATC	AAC	TTC
R	E	I	Q	L	D	L	E	M	I	T	V	N	T	V	I	N	F
1683	1692	1701	1710	1719	1728												
AGA	GGC	AGC	TCC	GTG	ATC	CGA	CTG	CGG	ATA	TAT	GTG	TCG	CAG	TAC	CCA	TTC	TGA
R	G	S	S	V	I	R	L	R	I	Y	V	S	Q	Y	P	F	
1737	1746	1755	1764	1773	1782												
GCC	TCG	GGC	TGG	AGC	CTC	CGA	CGC	TGC	CTC	TCA	TTG	GCA	CCA	AGG	GAC	AGG	AGA
1791	1800	1809	1818	1827	1836												
AGA	GAG	GAA	ATA	ACA	GAG	AGA	ATG	AGA	GCG	ACA	CAG	ACG	TTA	GGC	ATT	TCC	TGC
1845	1854	1863	1872	1881	1890												
TGA	ACG	TTT	CCC	CGA	AGA	GTC	AGC	CCC	GAC	TTC	CTG	ACT	CTC	ACC	TGT	ACT	ATT
1899	1908	1917	1926	1935	1944												
GCA	GAC	CTG	TCA	CCC	TGC	AGG	ACT	TGC	CAC	CCC	CAG	TTC	CTA	TGA	CAC	AGT	TAT
1953	1962	1971	1980	1989	1998												
CAA	AAA	GTA	TTA	TCA	TTG	CTC	CCC	TGA	TAG	AAG	ATT	GTT	GGT	GAA	T ^{TT} T	TCA	AGG

FIGURE 1E

6/17

2007	2016	2025	2034	2043	2052
CCT TCA GTT TAT TTC CAC TAT TTT CAA AGA AAA TAG ATT AGG TTT GCG GGG GTC					
2061	2070	2079	2088	2097	2106
TGA GTC TAT GTT CAA AGA CTG TGA ACA GCT TGC TGT CAC TTC TTC ACC TCT TCC					
2115	2124	2133	2142	2151	2160
ACT CCT TCT CTC ACT GTG TTA CTG CTT TGC AAA GAC CCG GGA GCT GGC GGG GAA					
2169	2178	2187	2196	2205	2214
CCC TGG GAG TAG CTA GTT TGC TTT TTG CGT ACA CAG AGA AGG CTA TGT AAA CAA					
2223	2232	2241	2250	2259	2268
ACC ACA GCA GGA TCG AAG GGT TTT TAG AGA ATG TGT TTC AAA ACC ATG CCT GGT					
2277	2286	2295	2304	2313	2322
ATT TTC AAC CAT AAA AGA AGT TTC AGT TGT CCT TAA ATT TGT ATA ACG GTT TAA					
2331	2340	2349	2358	2367	2376
TTC TGT CTT GTT CAT TTT GAG TAT TTT TAA AAA ATA TGT CGT AGA ATT CCT TCG					
2385	2394	2403	2412	2421	2430
AAA GGC CTT CAG ACA CAT GCT ATG TTC TGT CTT CCC AAA CCC AGT CTC CTC TCC					
2439	2448	2457	2466	2475	2484
ATT TTA GCC CAG TGT TTT CTT TGA GGA CCC CTT AAT CCT GCT TTC TTT AGA ATT					

FIGURE 1F

2493 2502 2511 2520 2529 2538
TTT ACC CAA TTG GAT TGG AAT GCA GAG GTC TCC AAA CTG ATT AAA TAT TTG AAG
2547
AGA AAA AAA AAA

FIGURE 1G

8/17

TG	GGT	GCA	AGC	TCA	CAA	CCG	TAA	CAG	CCA	GCA	36	45	54
63											90	99	108
CTT	CAC	ATC	CAG	ACT	TGC	CTG	AGA	GGA	CCC	ACC	TCT	GAG	TGT
117											144	153	162
TGC	CCC	AGG	ATG	GGG	ACC	ACA	GCC	AGA	GCA	GCC	TTG	ACC	TAT
M	G	T	T	A	R	A	R	A	A	L	V	L	TTG
V	A	S	A	S	E	G	G	F	T	A	T	Y	GCT
225											198	207	216
AGG	CCA	GAG	CAC	TTT	CAA	GAA	GTT	GGC	TAC	GCA	GCT	ACA	GGA
R	P	E	H	F	Q	E	V	G	Y	A	A	P	Q
279											243	252	261
TCC	CGA	AGC	CTC	CCC	ATG	GAT	CAC	CCT	GAC	TCC	TCT	CAG	CAT
S	R	S	L	P	M	D	H	P	D	S	S	Q	H
333											297	306	315
GAG	GGA	CAG	AGT	CAA	GTG	CAG	CCC	CCT	CCC	TCT	CAG	GGC	CCT
E	G	Q	S	Q	V	Q	P	P	P	S	Q	E	ACC

FIGURE 2A

9/17

387	CAG GAA AAG	CTG CTA	CCT GCC	CAA CTC	CCT GCT	GAA AAG	GAA GTC	GGT CCC	CCT	432
Q	E	K	L	P	A	Q	L	P	A	405
L	P	Q	E	V	A	P	L	Q	K	414
									E	423
441	CCT CAG GAA GCT	GTC CCC	CTC CAA	AAA GAG	CTG CCC	TCT CTC	CAG CAC	CCC	CCC	486
L	P	Q	E	A	V	P	L	Q	K	459
									E	468
495	AAT GAA CAG AAG	GAA GGA	ATG CCA	GCT CCA	TTT GGG	GAC CAG	AGC CAT	CCA GAA	CCA GAA	540
N	E	Q	K	E	G	M	P	A	P	504
									F	513
549	CCT GAG TCC TGG	AAT GCA	GCC CAG	CAC TGC	CAA CAG	GAC CGG	TCC CAA	GGG GGC	GGC	594
P	E	S	W	N	A	A	Q	H	C	567
									Q	576
603	TGG GGCG CAC CGG	CTG GAT	GGC TTC	CCC CCT	GGG CGG	CCT TCT	CCA GAC	AAT CTG	CTG	648
W	G	H	R	L	D	G	F	P	G	612
									R	621
657	AAC CAA ATC	TGC CTT	AAC CGT	CAG CAT	GTG TAT	GGT CCC	TGG AAC	AAC CTA	CTA	702
N	Q	I	C	L	P	N	R	Q	H	666
									V	675
711	CCA CAG TCC AGC	TAC TCC	CAC CTC	ACT CGC	CAG GGT	GAG ACC	CTC AAT	TTC CTG	CTG	756
P	Q	S	S	Y	S	H	L	T	R	720
									Q	729
									G	738
									E	747
									T	756
									L	756

FIGURE 2B

10/17

GAG	ATT	GGA	TAT	TCC	CGC	TGC	TGC	CAC	TGC	CGC	AGC	CAC	ACA	AAC	CGC	CTA	GAG
E	I	G	Y	S	R	C	C	H	C	R	S	H	T	N	R	L	E
819		828		837		846		846		855		855		864		864	
TGT	GCC	AAA	CTT	GTG	TGG	GAG	GAA	GCA	ATG	AGC	CGA	TTC	TGT	GAG	GCC	GAG	TTC
C	A	K	L	V	W	E	E	A	M	S	R	F	C	E	A	E	F
873		882		891		900		900		909		909		918		918	
TCG	GTC	AAG	ACC	CGA	CCC	CAC	TGG	TGG	TGC	ACG	CGG	CAG	GGG	GAG	GCT	CGG	TTC
S	V	K	T	R	P	H	W	C	C	T	R	Q	G	E	A	R	F
927		936		945		954		954		963		963		972		972	
TCC	TGC	TTC	CAG	GAG	GAA	GCT	CCC	CAG	CCA	CAC	TAC	CAG	CTC	CGG	GCC	TGC	CCC
S	C	F	Q	E	E	A	P	Q	P	H	Y	Q	L	R	A	C	P
981		990		999		1008		1008		1017		1017		1026		1026	
AGC	CAT	CAG	CCT	GAT	ATT	TCC	TCG	GGT	CTT	GAG	CTG	CCT	TTC	CCT	GGG	GGG	GTG
S	H	Q	P	D	I	S	S	G	L	E	L	P	F	P	P	G	V
1035		1044		1053		1062		1062		1071		1071		1080		1080	
CCC	ACA	TTG	GAC	AAT	ATC	AAG	AAC	ATC	TGC	CAC	CTG	AGG	CGC	TTC	CGC	TCT	GTG
P	T	L	D	N	I	K	N	I	C	H	L	R	R	F	R	S	V
1089		1098		1107		1116		1116		1125		1125		1134		1134	
CCA	CGC	AAC	CTG	CCA	GCT	ACT	GAC	CCC	CTA	CAA	AGG	GAG	CTG	CTG	GCA	CTG	ATC
P	R	N	L	P	A	T	D	P	L	Q	R	E	L	L	A	L	I

FIGURE 2C

11/17

CAG	CTG	GAG	AGG	GAG	TTC	CAG	CGC	TGC	TGC	CGC	CAG	GGG	AAC	AAT	CAC	ACC	TGT	1188
Q	L	E	R	E	F	Q	R	C	C	R	Q	G	N	N	H	T	C	
1197		1206				1215				1224				1233				1242
ACA	TGG	AAG	GCC	TGG	GAG	GAT	ACC	CTT	GAC	AAA	TAC	TGT	GAC	CGG	GAG	TAT	GCT	
T	W	K	A	W	E	D	T	L	D	K	Y	C	D	R	E	Y	A	
1251		1260				1269				1278				1287				1296
GTG	AAG	ACC	CAC	CAC	CAC	TTG	TTG	TGT	TGC	CGC	CAC	CCT	CCC	AGC	CCT	ACT	CGG	GAT
V	K	T	H	H	H	L	C	C	R	H	P	P	S	P	T	R	D	
1305		1314				1323				1332				1341				1350
GAG	TGC	TTT	GCC	CGT	CGG	GCT	CCT	TAC	CCC	AAC	TAT	GAC	CGG	GAC	ATC	TTG	ACC	
E	C	F	A	R	R	A	P	Y	P	N	Y	D	R	D	I	L	T	
1359		1368				1377				1386				1395				1404
ATT	GAC	ATC	GGT	CGA	GTC	ACC	CCC	AAC	CTC	ATG	GGC	CAC	CTC	TGT	GGA	AAC	CAA	
I	D	I	G	R	V	T	P	N	L	M	G	H	L	C	G	N	Q	
1413		1422				1431				1440				1449				1458
AGA	GTT	CTC	ACC	AAG	CAT	AAA	CAT	ATT	CCT	GGG	CTG	ATC	CAC	AAC	ATG	ACT	GCC	
R	V	L	T	K	H	K	H	I	P	G	L	I	H	N	M	T	A	
1467		1476				1485				1494				1503				1512
CGC	TGC	TGT	GAC	CTG	CCA	TTT	CCA	GAA	CAG	GCC	TGC	TGT	GCA	GAG	GAG	GAG	AAA	
R	C	C	D	L	P	F	P	E	Q	A	C	C	A	E	E	E	K	

FIGURE 2D

12/17

TTA	ACC	TTC	ATC	AAT	GAT	CTG	TGT	GGT	CCC	CGA	CGT	AAC	ATC	TGG	CGA	GAC	CCT	1566
L	T	F	I	N	D	L	C	G	P	R	R	N	I	W	R	D	P	
1521	1530	1539	1548	1557														
GCC	CTC	TGC	TGT	TAC	CTG	AGT	CCT	GGG	GAT	GAA	CAG	GTC	AAC	TGC	TTC	AAC	AAC	1620
A	L	C	C	Y	L	S	P	G	D	E	Q	V	N	C	F	N	I	
1575	1584	1593	1602	1611														
AAT	TAT	CTG	AGG	AAC	GTG	GCT	CTA	GTG	TCT	GGA	GAC	ACT	GAG	AAC	GCC	AAG	GCC	1674
N	Y	L	R	N	V	A	L	V	S	G	D	T	E	N	A	K	G	
1629	1638	1647	1656	1665														
CAG	GGG	GAG	CAG	GGC	TCA	ACT	GGA	GGA	ACA	AAT	ATC	AGC	TCC	ACC	TCT	GAG	CCC	1728
Q	G	E	Q	G	S	T	G	G	T	N	I	S	S	T	S	E	P	
1683	1692	1701	1710	1719														
AAG	GAA	GAA	TGA	GTC	ACC	CCA	GAG	CCC	TAG	AGG	GTC	AGA	TGG	GGG	GAA	CCC	CAC	1782
K	E	E																
1737	1746	1755	1764	1773														
CCT	GCC	CCA	CCC	ATC	TGA	ACA	CTC	ATT	ACA	CTA	AAC	ACC	TCT	TGG	ATT	TGG	TGT	1836
1791	1800	1809	1818	1827														
CCT	CAT	TGT	CTA	TCT	AAT	GTC	TCA	CCC	GCA	GTG	TTT	TAA	GTG	GAT	CTT	GGT	GCC	1890
1845	1854	1863	1872	1881														
CTG	GCC	CAG	G															
1899																		

FIGURE 2E

1	M P G I K R I L T V T I L A L C L P S P	45517
1	M A T S G V L P G G G F V A S A A A V A	GI 458228
21	G N A Q A Q C T N G F D L D R Q S G Q C	45517
21	G P E M Q T G R N N F V I R R N P A D -	GI 458228
41	L D I D E C R T I P E A C R G D M M C V	45517
40	- -	GI 458228
61	N Q N G G Y L C I P R T N P V Y R G P Y	45517
40	- -	GI 458228
81	S N P Y S T P Y S G P Y P A A A P P L S	45517
40	- P Q R	GI 458228
101	A P N Y P T I S R P L I C R F G Y Q M D	45517
43	I P S N P - - S H R I Q C A A G Y E Q S	GI 458228
121	E S N O C V D V D E C A T D S H Q C N P	45517
61	E H N V C Q D I D E C T A G T H N C R A	GI 458228
141	T Q I C I N T E G G Y T C S C T D G Y W	45517
81	D Q V C I N L R G S F A C C Q C P P G Y Q	GI 458228
161	L L E G Q C L D I D E C R Y G - Y C Q Q	45517
101	K R G E Q C V D I D E C T I P P Y C H Q	GI 458228
180	L C A N V P G S Y S C T C N P G F T L N	45517
121	R C V N T P G S F Y C Q C S P G F Q L A	GI 458228
200	E D G R S C Q D V N E C A T E N P C V Q	45517
141	A N N Y T C V D I N E C D A S N Q C A Q	GI 458228
220	T C V N T Y G S F I C R C D P G Y E L E	45517
161	Q C Y N I L G S F I C Q C N Q G Y E L S	GI 458228

FIGURE 3A

240	E D G V H C S D M D E C S F S E F L C Q	45517
181	S D R L N C E D I D E C R T S S Y L C Q	GI 458228
260	H E C V N Q O P G T Y F C S C P P G Y I L	45517
201	Y Q C V N E P G K F S C M C P Q G Y Q V	GI 458228
280	L D D N R S C Q D I N E C E H R N H T C	45517
221	V R - S R T C Q D I N E C E T T N E - C	GI 458228
300	N L Q Q T C Y N L Q G G F K C I D P I R	45517
239	R E D E M C W N Y H G G F R C Y P R N P	GI 458228
320	C E E P Y L R I S D N R C M C P A E N P	45517
259	C Q D P Y I L T P E N R C V C P V S N A	GI 458228
340	G C R D Q P F T I L Y R D M D V V S G R	45517
279	M C R E L P Q S I V Y K Y M S I R S D R	GI 458228
360	S V P A D I F Q M Q A T T R Y P G A Y Y	45517
299	S V P S D I F Q I Q A T T I Y A N T I N	GI 458228
380	I F Q I K S G N E G R E F Y M R Q T G P	45517
319	T F R I K S G N E N G E F Y L R Q T S P	GI 458228
400	I S A T L V M T R P I K G P R E I Q L D	45517
339	V S A M L V L V K S L S G P R E H I V D	GI 458228
420	L E M I T V N T V I N F R G S S V I R L	45517
359	L E M L T V S S I G T F R T S S V L R L	GI 458228
440	R I Y V S Q Y P F	45517
379	T I I V G P F S F	GI 458228

FIGURE 3B

1	M G T T A R A A L V L T Y L A V A S A A	1621777
1	M G T V S R A A L I L A C L A L A S A A	GI 496120
21	S E G G F T A T G Q R Q L R P E - - -	1621777
21	S E G A F K A S D Q R E M T P E R L F Q	GI 496120
37	H F Q E V G Y A A P P S P P L S R S L P	1621777
41	H L H E V G Y A A P P S L P Q T R R L R	GI 496120
57	M D H P D S S O H G P P - F E G Q S Q V	1621777
61	V D H S V T S L H D P P L F E E Q R E V	GI 496120
76	Q P P P S O E A T P L Q Q E K L L P A Q	1621777
81	Q P P S S P E D I P V Y E E D W P T F L	GI 496120
96	L P A E K E V G P P L P Q E A V P L Q K	1621777
101	N P N V D K A G P A V P Q E A I P L Q K	GI 496120
116	E L P S L Q - - - - - - - - - H P	1621777
121	E Q P P P Q V H I E Q K E I D P P A Q P	GI 496120
124	N E - - - Q K E G M P A P F G D Q S H P	1621777
141	Q E E I V Q K E V K P H T L A G Q L P P	GI 496120
141	E P E S W N A A Q H C Q Q D R S Q G G W	1621777
161	E P R T W N P A R H C Q Q G R - R G V W	GI 496120
161	G H R L D G F P P G R P S P D N L N Q I	1621777
180	G H R L D G F P P G R P S P D N L K Q I	GI 496120
181	C L P N R Q H V V Y G P W N L P Q S S Y	1621777
200	C L P E R Q H V I Y G P W N L P Q T G Y	GI 496120
201	S H L T R Q G E T L N F L E I G Y S R C	1621777
220	S H L S R Q G E T L N V L E T G Y S R C	GI 496120

FIGURE 4A

221 C H C R S H T N R L E C A K L V W E E A 1621777
 240 C P C R S D T N R L D C L K L V W E D A GI 496120

241 M S R F C E A E F S V K T R P H W C C T 1621777
 260 M T Q F C E A E F S V K T R P H L C C R GI 496120

261 R Q G E A R F S C F Q E E A P Q O P H Y Q 1621777
 280 L R G E E R F S C F Q K E A P R P D Y L GI 496120

281 L R A C P S H Q P D I S S G L E L P F P 1621777
 300 L R P C P V H Q N G M S S G P Q L P F P GI 496120

301 P G V P T L D N I K N I C H L R R F R S 1621777
 320 P G L P T P D N V K N I C L L R R F R A GI 496120

321 V P R N L P A T D P L Q R E L L A L I Q 1621777
 340 V P R N L P A T D A I Q R Q L Q A L T R GI 496120

341 L E R E F Q R C C R Q G N N H T C T W K 1621777
 360 L E T E F Q R C C R Q G H N H T C T W K GI 496120

361 A W E D T L D K Y C D R E Y A V K T H H 1621777
 380 A W E G T L D G Y C E R E L A I K T H P GI 496120

381 H L C C R H P P S P T R D E C F A R R A 1621777
 400 H S C C H Y P P S P A R D E C F A H L A GI 496120

401 P Y P N Y D R D I L T I D I G R V T P N 1621777
 420 P Y P N Y D R D I L T L D L S R V T P N GI 496120

421 L M G H L C G N Q R V L T K H K H I P G 1621777
 440 L M G Q L C G S G R V L S K H K Q I P G GI 496120

441 L I H N M T A R C C D L P F P E Q A C C 1621777
 460 L I Q N M T V R C C E L P Y P E Q A C C GI 496120

FIGURE 4B

17/17

461	A E E E K L T F I N D L C G P R R N I W	1621777
480	G E E E K L A F I E N L C G P R R N S W	GI 496120
481	R D P A L C C Y L S P G D E Q V N C F N	1621777
500	K D P A L C C D L S P E D K Q I N C F N	GI 496120
501	I N Y L R N V A L V S G D T E N A K G Q	1621777
520	T N Y L R N V A L V A G D T G N A T G L	GI 496120
521	G E Q G S T G G T N I S S T S E P K E E	1621777
540	G E Q G P T R G T D A N P A P G S K E E	GI 496120

FIGURE 4C

THIS PAGE BLANK (USP)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/485, 14/47, C12N 15/12 A61K 48/00		A3	(11) International Publication Number: WO 99/00410
(21) International Application Number: PCT/US98/13012		(43) International Publication Date: 7 January 1999 (07.01.99)	(43) International Publication Date: 7 January 1999 (07.01.99)
(22) International Filing Date: 23 June 1998 (23.06.98)		(74) Agent: BILLINGS, Lucy, J.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).	(74) Agent: BILLINGS, Lucy, J.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).
(30) Priority Data: 08/884,072 27 June 1997 (27.06.97) US		(81) Designated States: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	(81) Designated States: AT, AU, BR, CA, CH, CN, DE, DK, ES, FI, GB, IL, JP, KR, MX, NO, NZ, RU, SE, SG, US, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US 08/884,072 (CIP) Filed on 27 June 1997 (27.06.97)		(43) International Publication Date: 7 January 1999 (07.01.99)	(43) International Publication Date: 7 January 1999 (07.01.99)
(71) Applicant (for all designated States except US): INCYTE PHARMACEUTICALS, INC. [US/US]; 3174 Porter Drive, Palo Alto, CA 94304 (US).		(74) Agent: BILLINGS, Lucy, J.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).	(74) Agent: BILLINGS, Lucy, J.; Incyte Pharmaceuticals, Inc., 3174 Porter Drive, Palo Alto, CA 94304 (US).
(72) Inventors; and (75) Inventors/Applicants (for US only): BANDMAN, Olga [US/US]; 366 Anna Avenue, Mountain View, CA 94043 (US). CORLEY, Neil, C. [US/US]; 1240 Dale Avenue #30, Mountain View, CA 94040 (US). GUEGLER, Karl, J. [CH/US]; 1048 Oakland Avenue, Menlo Park, CA 94025 (US).		(88) Date of publication of the international search report: 18 March 1999 (18.03.99)	(88) Date of publication of the international search report: 18 March 1999 (18.03.99)

(54) Title: HUMAN EXTRACELLULAR MATRIX PROTEINS

9	18	27	36	45	54
CCA AGA TTG TTG TGA GGA GTC TAG	CCA GTC	GTT GAG CGC TGT	AAT CTG AAC CAG		
63	72	81	90	99	108
CTG TGT CCA GAC TGA GGC CCC ATT	TGC ATT ATT	TAA CAT ACT	ACT TAG AAA ATG AAG		
117	126	135	144	153	162
TGT TCA TTT TTA ACA TTC CTC CTC	CAA TTG GTT TAA TGC	TGA ATT ACT	GAA GAG		
171	180	189	198	207	216
GGC TAA GCA AAA CCA GGT GCT TGC GCT	GAG GGC TCT GCA GTG	GCT GGG AGG ACC			
225	234	243	252	261	270
CCG GCG CTC TCC CCG TGT CCT CTC	CAC GAC TCG CTC	GGC CCC TCT GGA ATA AAA			
279	288	297	306	315	324
CAC CCG CGA GCC CCG AGG GCC CAG	AGG CCG ACG TGC	CCG AGC TCC TCC GGG			
333	342	351	360	369	378
GGT CCC GCC CGC GAG CTT TCT CGC CTT	CGC ATC TCC TCC	TCG CGC GTC TTG			
387	396	405	414	423	432
GAC ATG CCA GGA ATA AAA AGG ATA CTC	ACT GTT ACC ATT CTG	GCT CTC TGT CTT			
M P G I K R I L T V T I L A L C L					

(57) Abstract

The invention provides two human extracellular matrix proteins (ECMP) and polynucleotides which identify and encode ECMP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of ECMP.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/US 98/13012

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07K14/485 C07K14/47 C12N15/12 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>BHALERAO J ET AL: "MOLECULAR CLONING, CHARACTERIZATION, AND GENETIC MAPPING OF THE CDNA CODING FOR A NOVEL SECRETORY PROTEIN OF MOUSE. DEMONSTRATION OF ALTERNATIVE SPLICING IN SKIN AND CARTILAGE" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 27, 7 July 1995, pages 16385-16394, XP002040187 cited in the application</p> <p style="text-align: center;">---</p> <p style="text-align: center;">-/--</p>	1

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

*** Special categories of cited documents :**

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

1 December 1998

Date of mailing of the international search report

28/12/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Mateo Rosell, A.M.

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	LECKA-CZERNIK B ET AL: "AN OVEREXPRESSED GENE TRANSCRIPT IN SENESCENT AND QUIESCENT HUMAN FIBROBLASTS ENCODING A NOVEL PROTEIN IN THE EPIDERMAL GROWTH FACTOR-LIKE REPEAT FAMILY STIMULATES DNA-SYNTHESIS" MOLECULAR AND CELLULAR BIOLOGY, vol. 15, no. 1, January 1995, pages 120-128, XP002036980 cited in the application see the whole document ----	1
P,X	WO 97 38002 A (HUMAN GENOME SCIENCES INC) 16 October 1997 see the whole document and specially Figure 1A-D. ----	1-7
P,X	WO 97 39123 A (GENETICS INST) 23 October 1997 see the whole document and specially SEQ.ID.N.14 and 15. ----	1,3
P,X	WO 97 39122 A (MURO PHARMACEUTICAL INC) 23 October 1997 see the whole document and specially pages 82-83. ----	1,3
T	DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 1 October 1998, XP002086216 HINXTON, GB AC= AF093118. Homo sapiens UP50, similar to human S1-5; possible membrane and extracellular matrix protein, urine p50 protein. -----	2,3

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/13012

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9738002	A 16-10-1997	AU 5549296	A	29-10-1997
WO 9739123	A 23-10-1997	AU 2732997	A	07-11-1997
		AU 2734497	A	07-11-1997
		AU 2801697	A	07-11-1997
		WO 9739102	A	23-10-1997
		WO 9739030	A	23-10-1997
WO 9739122	A 23-10-1997	AU 2456397	A	07-11-1997

THIS PAGE BLANK (USPTO)